MCID: PRK057
MIFTS: 72

Parkinson Disease, Late-Onset malady

Categories: Genetic diseases, Neuronal diseases, Mental diseases, Rare diseases, Metabolic diseases

Aliases & Classifications for Parkinson Disease, Late-Onset

About this section

Aliases & Descriptions for Parkinson Disease, Late-Onset:

Name: Parkinson Disease, Late-Onset 50 33
Parkinson Disease 50 11 22 46 23 24 68 48 37 66
Parkinson's Disease 33 11 46 24 47 13 25 36
Primary Parkinsonism 46 24 68
Paralysis Agitans 11 46 68
Late Onset Parkinson Disease 68 25
 
Pd 24 68
Parkinson Disease, Late-Onset, Susceptibility to 12
Idiopathic Parkinson Disease 68
Lewy Body Parkinson Disease 68
Shaking Palsy 46
Park 68

Characteristics:

HPO:

62
parkinson disease, late-onset:
Onset and clinical course: insidious onset, progressive


Classifications:



External Ids:

OMIM50 168600
Disease Ontology11 DOID:14330
ICD1028 G20
ICD9CM30 332, 332.0
MeSH37 D010300
NCIt43 C26845

Summaries for Parkinson Disease, Late-Onset

About this section
OMIM:50 Parkinson disease was first described by James Parkinson in 1817. It is the second most common neurodegenerative... (168600) more...

MalaCards based summary: Parkinson Disease, Late-Onset, also known as parkinson disease, is related to parkinson disease 1 and parkinson disease 6, early onset, and has symptoms including hallucinations, dysautonomia and urinary urgency. An important gene associated with Parkinson Disease, Late-Onset is GBA (Glucosylceramidase Beta), and among its related pathways are Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. and Neuroscience. The drugs amantadine and trihexyphenidyl hydrochloride have been mentioned in the context of this disorder. Affiliated tissues include brain, subthalamic nucleus and testes, and related mouse phenotypes are taste/olfaction and cellular.

Disease Ontology:11 A synucleinopathy that has material basis in degeneration of the central nervous system that often impairs motor skills, speech, and other functions.

NIH Rare Diseases:46 Parkinson disease belongs to a group of conditions called movement disorders. the four main symptoms are tremor, or trembling in hands, arms, legs, jaw, or head; rigidity, or stiffness of the limbs and trunk; bradykinesia, or slowness of movement; and postural instability, or impaired balance. these symptoms usually begin gradually and worsen with time.  as they become more pronounced, patients may have difficulty walking, talking, or completing other simple tasks.  not everyone with one or more of these symptoms has parkinson disease, as the symptoms sometimes appear in other diseases as well. parkinson disease affects about 1 to 2 percent of people over the age of 60 years and the chance of developing parkinson disease increases as we age. although some parkinson disease cases appear to be hereditary most cases are sporadic and occur in people with no apparent history of the disorder in their family. when three or more people are affected in a family, especially if they are diagnosed at an early age (under 50 years)  there may be a gene making this family more likely to develop the condition. currently, seven genes that cause some form of parkinson's disease have been identified. mutations (changes) in three known genes called snca (park1),uchl1 (park 5), and lrrk2 (park8) and another mapped gene (park3) have been reported in families with dominant inheritance. mutations in three known genes, park2 (park2), park7 (park7), and pink1 (park6) have been found in affected individuals who had siblings with the condition but whose parents did not have parkinson's disease (recessive inheritance). there is some research to suggest that these genes are also involved in early-onset parkinson's disease (diagnosed before the age of 30) or in dominantly inherited parkinson's disease but it is too early yet to be certain. however, in most cases inheriting a mutation will not cause someone to develop parkinson's disease because there may be additional genes and environmental factors determining who will get the condition, when they get it and how it affects them.  last updated: 11/5/2015

UniProtKB/Swiss-Prot:68 Parkinson disease: A complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability. Additional features are characteristic postural abnormalities, dysautonomia, dystonic cramps, and dementia. The pathology of Parkinson disease involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. The disease is progressive and usually manifests after the age of 50 years, although early-onset cases (before 50 years) are known. The majority of the cases are sporadic suggesting a multifactorial etiology based on environmental and genetic factors. However, some patients present with a positive family history for the disease. Familial forms of the disease usually begin at earlier ages and are associated with atypical clinical features.

MedlinePlus:36 Parkinson's disease (pd) is a type of movement disorder. it happens when nerve cells in the brain don't produce enough of a brain chemical called dopamine. sometimes it is genetic, but most cases do not seem to run in families. exposure to chemicals in the environment might play a role. symptoms begin gradually, often on one side of the body. later they affect both sides. they include trembling of hands, arms, legs, jaw and face stiffness of the arms, legs and trunk slowness of movement poor balance and coordination as symptoms get worse, people with the disease may have trouble walking, talking, or doing simple tasks. they may also have problems such as depression, sleep problems, or trouble chewing, swallowing, or speaking. there is no lab test for pd, so it can be difficult to diagnose. doctors use a medical history and a neurological examination to diagnose it. pd usually begins around age 60, but it can start earlier. it is more common in men than in women. there is no cure for pd. a variety of medicines sometimes help symptoms dramatically. surgery and deep brain stimulation (dbs) can help severe cases. with dbs, electrodes are surgically implanted in the brain. they send electrical pulses to stimulate the parts of the brain that control movement. nih: national institute of neurological disorders and stroke

NINDS:47 Parkinson's disease (PD) belongs to a group of conditions called motor system disorders, which are the result of the loss of dopamine-producing brain cells. The four primary symptoms of PD are tremor, or trembling in hands, arms, legs, jaw, and face; rigidity, or stiffness of the limbs and trunk; bradykinesia, or slowness of movement; and postural instability, or impaired balance and coordination. As these symptoms become more pronounced, patients may have difficulty walking, talking, or completing other simple tasks. PD usually affects people over the age of 60.

Genetics Home Reference:24 Parkinson disease is a progressive disorder of the nervous system. The disorder affects several regions of the brain, especially an area called the substantia nigra that controls balance and movement.

Wikipedia:69 Parkinson\'s disease (PD) is a long term disorder of the central nervous system that mainly affects the... more...

GeneReviews summary for NBK1223

Related Diseases for Parkinson Disease, Late-Onset

About this section

Diseases in the Parkinson Disease, Late-Onset family:

Parkinson Disease 7, Autosomal Recessive Early-Onset Parkinson Disease 6, Early Onset
Parkinson Disease 19, Juvenile-Onset Parkinson Disease 10
Parkinson Disease 16 Parkinson Disease 13
Parkinson Disease 11 Parkinson Disease 21
Parkinson Disease 18 Parkinson Disease 5
Parkinson Disease 4 Parkinson Disease 1
Parkinson Disease, Juvenile, Type 2 Parkinson Disease 8
Parkinson Disease 17 Parkinson Disease 20, Early-Onset
Parkinson Disease 15, Autosomal Recessive Parkinson Disease 14, Autosomal Recessive
Parkinson Disease 12 Lrrk2-Related Parkinson Disease
Parkinson Disease Type 3 Parkinson Disease Type 9
Dnajc6-Related Parkinson Disease Eif4g1-Related Parkinson Disease
Gigyf2-Related Parkinson Disease Pla2g6-Related Parkinson Disease
Synj1-Related Parkinson Disease Fbxo7-Related Parkinson Disease
Htra2-Related Parkinson Disease Park7-Related Parkinson Disease
Snca-Related Parkinson Disease Vps35-Related Parkinson Disease
Hereditary Late-Onset Parkinson Disease Parkinson Disease 22
Parkinson Disease 23, Autosomal Recessive, Early Onset

Diseases related to Parkinson Disease, Late-Onset via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 94)
idRelated DiseaseScoreTop Affiliating Genes
1parkinson disease 135.1GBA, LRRK2, MAPT, PARK2, SLC6A3, SNCA
2parkinson disease 6, early onset35.1LRRK2, PARK2, PARK7, PINK1
3parkinson disease 1034.9LRRK2, PARK2, PARK7, PINK1, SNCA
4parkes weber syndrome12.3
5parkinson disease, juvenile, type 212.3
6parkinson disease 15, autosomal recessive12.2
7paralysis agitans, juvenile, of hunt12.1
8postencephalitic parkinson disease12.1
9parkinson disease 812.1
10parkinson disease 1812.1
11parkinson disease 512.1
12parkinson disease 412.1
13parkinson disease 7, autosomal recessive early-onset12.1
14lrrk2-related parkinson disease12.1
15parkinson disease 1112.1
16parkinson disease 1712.1
17parkinson disease 1312.1
18parkinson disease 14, autosomal recessive12.1
19parkinson disease 2212.0
20pink1 type of young-onset parkinson disease12.0
21parkinson disease 2112.0
22parkinson disease 20, early-onset12.0
23parkinson disease 23, autosomal recessive, early onset12.0
24parkin type of early-onset parkinson disease12.0
25parkinson disease 19, juvenile-onset12.0
26hereditary late-onset parkinson disease12.0
27parkinson disease type 311.9
28parkinson disease susceptibility11.9
29parkes weber syndrome, rasa1-related11.9
30parkinson disease 1611.9
31pla2g6-related parkinson disease11.9
32snca-related parkinson disease11.9
33parkinson disease 1211.9
34eif4g1-related parkinson disease11.9
35gigyf2-related parkinson disease11.9
36htra2-related parkinson disease11.9
37mt-tt related parkinson disease susceptibility11.9
38parkinson disease type 911.8
39fbxo7-related parkinson disease11.8
40prolidase deficiency11.5
41pendred syndrome11.4
42parkinson disease, late-onset11.4ADH1C, ATXN2, ATXN3, ATXN8OS, DNAJC13, GBA
43phka2-related phosphorylase kinase deficiency11.3ADH1C, ATXN2, GBA, LRRK2, MAPT, PARK2
44angiomyolipoma11.3ATXN3, GDNF, LRRK2, MAOB, MAPT, PARK2
45chronic intestinal vascular insufficiency11.3ATXN3, GDNF, LRRK2, MAOB, MAPT, PARK2
46adrenal gland pheochromocytoma11.3GDNF, LRRK2, MAOB, MAPT, PARK2, PARK7
47meier-gorlin syndrome 511.3LRRK2, MAPT, PARK2, PARK7, SLC6A3, SNCA
48celiac disease 1211.3LRRK2, PARK2, PARK7, PINK1, SNCA, VPS13C
49angelman syndrome due to imprinting defect in 15q11-q1311.3DNAJC13, GBA, LRRK2, SNCA, VPS35
50mast syndrome11.2LRRK2, MAPT, PARK2, PARK7, PINK1, SNCA

Comorbidity relations with Parkinson Disease, Late-Onset via Phenotypic Disease Network (PDN):

(show top 50)    (show all 53)
Alzheimer DiseaseAnxiety Disorder
Atypical Depressive DisorderBipolar Disorder
Cerebral DegenerationCommunicating Hydrocephalus
Deficiency AnemiaDelusional Disorder
Dependent Personality DisorderDysthymic Disorder
HypothyroidismIron Deficiency Anemia
LeukodystrophyMajor Affective Disorder-7
Major Depressive Disorder and Accelerated Response to Antidepressant Drug TreatmentMarasmus
Mood DisorderObstructive Hydrocephalus
Paranoid SchizophreniaActive Peptic Ulcer Disease
Acute ConjunctivitisAcute Cystitis
Autonomic Nervous System DiseaseBlepharitis
BronchitisBronchopneumonia
Cerebral AtherosclerosisCerebrovascular Disease
ConjunctivitisCoronary Artery Disease
CystitisDecubitus Ulcer
EncephalopathyErythematosquamous Dermatosis
EsophagitisFecal Incontinence
Generalized AtherosclerosisHeart Disease
Intestinal VolvulusMegacolon
Neurogenic BladderOsteoporosis
Paralytic IleusProstatic Hypertrophy
Pseudobulbar PalsySwallowing Disorders
Tardive DyskinesiaTransient Cerebral Ischemia
Pernicious AnemiaPersonality Disorder

Graphical network of the top 20 diseases related to Parkinson Disease, Late-Onset:



Diseases related to parkinson disease, late-onset

Symptoms for Parkinson Disease, Late-Onset

About this section

Symptoms by clinical synopsis from OMIM:

168600

Clinical features from OMIM:

168600

HPO human phenotypes related to Parkinson Disease, Late-Onset:

(show all 22)
id Description Frequency HPO Source Accession
1 hallucinations occasional (7.5%) HP:0000738
2 dysautonomia occasional (7.5%) HP:0002459
3 urinary urgency HP:0000012
4 mask-like facies HP:0000298
5 depression HP:0000716
6 dementia HP:0000726
7 personality changes HP:0000751
8 dysarthria HP:0001260
9 parkinsonism HP:0001300
10 dystonia HP:0001332
11 weak voice HP:0001621
12 dysphagia HP:0002015
13 constipation HP:0002019
14 rigidity HP:0002063
15 bradykinesia HP:0002067
16 postural instability HP:0002172
17 resting tremor HP:0002322
18 sleep disturbance HP:0002360
19 neuronal loss in central nervous system HP:0002529
20 short stepped shuffling gait HP:0007311
21 substantia nigra gliosis HP:0011960
22 lewy bodies HP:0100315

UMLS symptoms related to Parkinson Disease, Late-Onset:


back pain, headache, myoclonus, pain, sciatica, seizures, syncope, tremor, chronic pain, cogwheel rigidity, bradykinesia, vertigo/dizziness, equilibration disorder, parkinsonian tremor, sleeplessness, parkinsonian rest tremor, freezing phenomenon, trembling; paralysis, tremor; parkinson's, constipation, muscle rigidity, sleep disturbances, sense of smell impaired

Drugs & Therapeutics for Parkinson Disease, Late-Onset

About this section

Drugs for Parkinson Disease, Late-Onset (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 239)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
SerotoninPhase 4, Phase 3, Phase 2, Phase 1351050-67-95202
Synonyms:
3-(2-Aminoethyl)-1H-indol-5-ol
3-(2-Aminoethyl)indol-5-ol
3-(b-Aminoethyl)-5-hydroxyindole
5-HT
5-HTA
5-Hydroxy-3-(b-aminoethyl)indole
 
5-Hydroxy-tryptamine
5-Hydroxyltryptamine
5-Hydroxytriptamine
5-Hydroxytryptamine
Antemovis
DS substance
Enteramin
Enteramine
2Quetiapine FumaratePhase 4407111974-72-2
3
imidazolePhase 432288-32-4795
Synonyms:
1,3-Diaza-2,4-cyclopentadiene
1,3-Diazole
1H-Imidazole
Glyoxalin
Glyoxaline
 
IMD
Imidazol
Iminazole
Imutex
Miazole
Pyrro(b)monazole
{Pyrro[b]monazole}
4vitamin dPhase 4, Phase 21607
5calcium channel blockersPhase 4, Phase 3, Phase 21889
6
PropofolPhase 49852078-54-84943
Synonyms:
2, 6-Diisopropylphenol
2,6 Diisopropylphenol
2,6-Bis(1-methylethyl)phenol
2,6-Bis(Isopropyl)-phenol
2,6-DIISOPROPYLPHENOL
2,6-Diisopropyl phenol
2,6-Diisopropylphenol
2,6-bis(1-methylethyl)-phenol
2,6-di(propan-2-yl)phenol
2078-54-8
28449-97-0
4-06-00-03435 (Beilstein Handbook Reference)
50356-15-5
AB00513968
AC-2038
AC1L1J9Y
AC1Q1OUI
AI3-26295
AM-149
Abbott Brand of Propofol
Alpha Brand of Propofol
Ampofol
Aquafol
Astra Brand of Propofol
AstraZeneca Brand of Propofol
BIDD:GT0436
BPBio1_000950
BPBio1_000969
BRD-K82255054-001-03-5
BRN 1866484
BSPBio_000862
Biomol-NT_000248
Braun Brand of Propofol
C07523
C12H18O
CAS-2078-54-8
CCRIS 9000
CHEBI:44915
CHEMBL526
CID4943
CPD-11437
CPD000059151
Curamed Brand of Propofol
D00549
D015742
D0617
D126608
D126608_ALDRICH
DB00818
DDS-04F
Diisopropylphenol
Dipravan
Diprivan
Diprivan (TN)
Diprivan Injectable emulsion
Disoprivan
Disoprofol
EINECS 218-206-6
EU-0100437
Fresenius Brand of Propofol
Fresenius Kabi Brand of Propofol
Fresofol
HMS1570L04
HMS2089O21
HMS2094E17
 
HSDB 7123
ICI 35,868
ICI 35868
ICI-35,868
ICI-35868
ICI35,868
ICI35868
InChI=1/C12H18O/c1-8(2)10-6-5-7-11(9(3)4)12(10)13/h5-9,13H,1-4H
Ivofol
Jsp004266
Juste Brand of Propofol
LS-996
Lopac-D126608
Lopac0_000437
MLS001066348
MLS001335999
MLS002454360
MolPort-001-794-517
NCGC00015389-01
NCGC00015389-02
NCGC00015389-04
NCGC00015389-09
NCGC00091538-01
NCGC00091538-02
NCGC00091538-03
NCGC00091538-04
NCGC00091538-05
NCGC00091538-06
NSC 5105
NSC5105
PFL
Parnell Brand of Propofol
Pisa Brand of Propofol
Prestwick0_000931
Prestwick1_000931
Prestwick2_000931
Prestwick3_000931
Propofol
Propofol (JAN/USAN/INN)
Propofol Abbott
Propofol Fresenius
Propofol IDD-D
Propofol MCT
Propofol Rovi
Propofol [USAN:INN:BAN]
Propofol(2,6-Diisopropylphenol)
Propofol-Lipuro
Propofolum
Propofolum [Latin]
Rapinovet
Recofol
Rovi Brand of Propofol
S01-0189
SAM002264610
SMR000059151
SPBio_003031
SPECTRUM1505022
ST50405911
Schering Brand of Propofol
UNII-YI7VU623SF
W505102_ALDRICH
ZD-0859
ZINC00968303
Zeneca Brand of Propofol
ghl.PD_Mitscher_leg0.558
nchembio.552-comp7
propofol
7Sildenafil citratePhase 4, Phase 2315171599-83-0
8
DexmedetomidinePhase 4, Phase 2, Phase 351576631-46-4, 113775-47-668602, 5311068, 56032
Synonyms:
(+)-4-((S)-alpha,2,3-Trimethylbenzyl)imidazole
(+)-4-((S)-alpha,2,3-trimethylbenzyl)imidazole
(+)-medetomidine
(S)-medetomidine
113775-47-6
4-[(1S)-1-(2,3-Dimethylphenyl)ethyl]-1H-imidazole
4-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole
5-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole
AC1NSJXT
C07450
CHEBI:4466
CHEMBL778
CID5311068
D00514
DEXMEDETOMIDINE
 
Dexdor (T)
Dexmedetomidin
Dexmedetomidina
Dexmedetomidine
Dexmedetomidine (USAN/INN)
Dexmedetomidinum
Dexmédétomidine
MPV 1440
MPV-1440
Medetomidina [Spanish]
Medetomidine
Medetomidinum [Latin]
NCGC00025347-01
PRECEDEX
Precedex (TN)
Tocris-2023
ZINC04632106
9talipexolePhase 41101626-70-4
10
TolcaponePhase 416134308-13-74659569
Synonyms:
(3,4-Dihydroxy-5-nitrophenyl)(4-methylphenyl)methanone
(3,4-dihydroxy-5-nitrophenyl)(4-methylphenyl)methanone
(3,4-dihydroxy-5-nitrophenyl)-(4-methylphenyl)methanone
134308-13-7
3,4-Dihydroxy-4'-methyl-5-nitrobenzophenone
3,4-Dihydroxy-5-nitro-4'-methylbenzophenone
3,4-dihydroxy-5'-methyl-5-nitrobenzophenone
4'-Methyl-3,4-dihydroxy-5-nitrobenzophenone
AC-791
AC1NFJIT
BIDD:GT0032
C066340
C07949
C14H11NO5
CCRIS 7904
CHEBI:367825
CHEMBL1324
CID4659569
CPD-7664
D00786
 
DB00323
FT-0082597
HMS2089K14
I14-13303
InChI=1/C14H11NO5/c1-8-2-4-9(5-3-8)13(17)10-6-11(15(19)20)14(18)12(16)7-10/h2-7,16,18H,1H
LS-91226
Methanone,(3,4-dihydroxy-5-nitrophenyl)(4-methylphenyl)
MolPort-003-850-570
NCGC00181767-01
Ro 40-7592
Ro-40-7592
Roche brand of tolcapone
Tasmar
Tasmar (TN)
Tolcapon
Tolcapona
Tolcapone
Tolcapone (JAN/USAN/INN)
Tolcapone [USAN:INN]
Tolcaponum
UNII-CIF6334OLY
11benserazidePhase 4, Phase 3, Phase 2, Phase 118
12
Citric AcidPhase 4, Phase 2106377-92-9311
Synonyms:
2-Hydroxy-1,2,3-propanetricarboxylate
2-Hydroxy-1,2,3-propanetricarboxylic acid
2-Hydroxytricarballylic acid
3-Carboxy-3-hydroxypentane-1,5-dioate
3-Carboxy-3-hydroxypentane-1,5-dioic acid
Aciletten
Anhydrous citrate
Anhydrous citric acid
Chemfill
Citraclean
 
Citrate
Citretten
Citric acid
Citro
Citronensäure
E 330
Hydrocerol A
Kyselina citronova
Suby G
Uro-trainer
beta-Hydroxytricarballylate
beta-Hydroxytricarballylic acid
13diureticsPhase 41338
14
HydrochlorothiazidePhase 439858-93-53639
Synonyms:
125727-50-6
3,4-Dihydro-6-chloro-7-sulfamyl-1,2, 4-benzothi
3,4-Dihydrochlorothiazide
58-93-5
6-Chloro-7-sulfamoyl-3, 4-dihy
8049-49-8
AB00052012
AC-11072
AC1L1GDT
AC1Q55FM
AF-614/30832002
AKOS000121373
ARONIS24316
Acesistem
Acuilix
Acuretic
Aldactazide
Aldactazide 25/25
Aldazida
Aldectazide 50/50
Aldoril
Ambap58-93-5
Apo-Hydro
Apresazide
Aquarills
Aquarius
Aquazide H
Aquazide-H
BAS 00371709
BIDD:GT0153
BPBio1_000019
BRD-K13078532-001-05-2
BRN 0625101
BSPBio_000017
BSPBio_002132
Bio-0714
Bremil
Briazide
C7H8ClN3O4S2
CAS-58-93-5
CCRIS 2082
CHEMBL435
CID3639
CPD000035778
Caplaril
Capozide
Carozide
Catiazida
Chlorizide
Chlorosulthiadil
Chlorothiazide
Chlorsulfonamidodihydrobenzothiadiazine dioxide
Chlorzide
Chlothia
Cidrex
Clorana
Component of Butizide Prestabs
Concor Plus
Condiuren
D00340
D006852
DB00999
Diaqua
Dichlorosal
Dichlorotride
Dichlothiazide
Dichlotiazid
Dichlotride
Diclotride
Dicyclotride
Didral
Dihydran
Dihydrochlorothiazid
Dihydrochlorothiazide
Dihydrochlorothiazidum
Dihydrochlorurit
Dihydrochlorurite
Dihydroxychlorothiazidum
Direma
Disalunil
Disothiazid
Diu 25 Vigt
Diu-Melusin
Diu-melusin
Diuril
Diurogen
DivK1c_000289
Dixidrasi
Drenol
Dyazide
EINECS 200-403-3
EU-0100614
Esidrex
Esidrix
Esidrix (TN)
Esimil
Esoidrina
FT-0082750
Fluvin
H 4759
H1274
H2910_SIAL
H4759_SIAL
HCT
HCT-Isis
HCTZ
HCZ
HMS1568A19
HMS1920D19
HMS2091L05
HMS500O11
HMS553N04
HSDB 3096
Hidril
Hidro-Niagrin
Hidrochlortiazid
Hidroclorotiazida
Hidroclorotiazida [INN-Spanish]
Hidroronol
Hidrosaluretil
Hidrotiazida
Hyclosid
Hydrex-semi
Hydril
Hydro Par
Hydro-Aquil
Hydro-D
Hydro-Diuril
Hydro-Saluric
Hydro-T
Hydro-chlor
HydroDIURIL
Hydrochlorat
Hydrochloro Thiazide
Hydrochlorot
Hydrochlorothiazid
Hydrochlorothiazide
Hydrochlorothiazide (JP15/USP/INN)
Hydrochlorothiazide Intensol
Hydrochlorothiazide [INN:BAN:JAN]
 
Hydrochlorothiazidum
Hydrochlorothiazidum [INN-Latin]
Hydrochlorthiazide
Hydrochlorthiazidum
Hydrocot
Hydrodiuretic
Hydrodiuril
Hydropres
Hydrosaluric
Hydrothide
Hydrozide
Hydrozide Injection, Veterinary
Hypothiazid
Hypothiazide
Hytrid
Hyzaar
I09-0531
IDI1_000289
Idroclorotiazide
Idroclorotiazide [DCIT]
Idrotiazide
Inderide
Inderide 80/25
Indroclor
Ivaugan
Jen-Diril
KBio1_000289
KBio2_001357
KBio2_003925
KBio2_006493
KBio3_001352
KBioGR_000351
KBioSS_001357
LS-243
Lopac-H-4759
Lopac0_000614
Lopressor HCT
Lotensin HCT
Lotensin Hct
MLS000069619
Manuril
Maschitt
Maxzide
Maybridge Compound 10
Maybridge1_004336
Mazide 25 mg
Medozide
Megadiuril
Microzide
Microzide (TN)
Mictrin
Mikorten
Modurcen
Moduretic
MolPort-000-144-465
NCGC00015508-01
NCGC00015508-02
NCGC00015508-03
NCGC00015508-07
NCGC00015508-12
NCGC00021906-03
NCGC00021906-04
NCGC00021906-05
NCGC00021906-06
NCGC00021906-07
NCGC00021906-08
NCI-C55925
NCI60_004317
NINDS_000289
NSC 53477
NSC53477
Natrinax
Nefrix
Nefrol
Neo-Codema
Neo-Flumen
Neo-Minzil
Neo-codema
Neoflumen
Newtolide
Novodiurex
Oprea1_357174
Oretic
Pantemon
Panurin
Prestwick0_000009
Prestwick1_000009
Prestwick2_000009
Prestwick3_000009
Prestwick_263
Prinzide
Raunova Plus
Ro-Hydrazide
Ro-hydrazide
Roxane
S1708_Selleck
SAM002554901
SMR000035778
SPBio_001259
SPBio_001938
SPECTRUM1500335
STK315354
Saldiuril
Sectrazide
Selozide
Ser-Ap-Es
Servithiazid
Spectrum2_001040
Spectrum3_000456
Spectrum4_000006
Spectrum5_000824
Spectrum_000877
Spironazide
Su 5879
Tandiur
Thiaretic
Thiuretic
Thlaretic
Timolide
UNII-0J48LPH2TH
Unazid
Unipres
Urodiazin
Urozide
Vaseretic
Vetidrex
WLN: T66 BSWM EM DHJ HG ISZW
ZINC00896569
Ziac
Zide
adiazine-1,1-dioxide
component of Aldactazide
component of Aldoril
component of Caplaril
component of Cyclex
component of Dyazide
component of Esimil
diclot ride
dro-2H-1,2,4-benzothiadiazine 1,1-dioxide
hydrochlorothiazide
panurin dichloride
15
DroxidopaPhase 4, Phase 3, Phase 2, Phase 12823651-95-8443940
Synonyms:
DOPS
Droxydopa
 
L-DOPS
L-Dihydroxyphenylserine
L-Threo-3,4-dihydroxyphenylserine
L-threo-dihydroxyphenylserine
16
NicotinePhase 4, Phase 2, Phase 1101654-11-5942, 89594
Synonyms:
(−
(+)-Nicotine
(+-)-3-(1-Methyl-2-pyrrolidinyl)pyridine
(+-)-Nicotine
(-)-3-(1-Methyl-2-pyrrolidyl)pyridine
(-)-3-(N-Methylpyrrolidino)pyridine
(-)-Nicotine
(-)-Nicotine solution
(2S) 3-(1-Methyl-pyrrolidin-2-yl)-pyridine
(R)-3-(1-Methyl-2-pyrrolidinyl)pyridine
(R,S)-Nicotine
(R,S)-nicotine
(RS)-nicotine
(S)-(-)-NICOTINE, 3-[(2S)-1-METHYL-2-PYRROLIDINYL] PYRIDINE
(S)-(-)-Nicotine
(S)-3-(1-methylpyrrolidin-2-yl)pyridine
(S)-3-(N-methylpyrrolidin-2-yl)pyridine
(S)-Nicotine
(±)-nicotine
)-1-Methyl-2-(3-pyridyl)pyrrolidine
)-Nicotine
)-Nicotine solution
1-Methyl-2-(3-pyridal)-Pyrrolidine
1-Methyl-2-(3-pyridal)-pyrrolidene
1-Methyl-2-(3-pyridiyl)pyrrolidine
1-Methyl-2-(3-pyridyl)pyrrolidine
1uw6
2'-beta-H-Nicotine
3-(1-Methyl-2-pyrollidinyl)pyridine
3-(1-Methyl-2-pyrrolidinyl)-Pyridine
3-(1-Methyl-2-pyrrolidinyl)pyridine
3-(1-Methylpyrrolidin-2-yl)pyridine
3-(2-(N-methylpyrrolidinyl))pyridine
3-(N-Methylpyrollidino)pyridine
3-(N-Methylpyrrolidino)pyridine
3-N-Methylpyrrolidine
3-[(2S)-1-methylpyrrolidin-2-yl]pyridine
36733_FLUKA
36733_RIEDEL
434F7990-3240-4A43-ACEC-E6CC1E495FA0
46343_FLUKA
46343_RIEDEL
54-11-5
AC1L3I79
AC1Q3ZOC
AI3-03424
BB_NC-0777
BIDD:GT0599
BRD-K05395900-322-02-1
Black Leaf
Black Leaf 40
C00745
CCRIS 1637
CHEBI:17688
CHEMBL3
CID89594
CPD000059074
Campbell's Nico-Soap
Caswell No. 597
Commit
D-Nicotine
D03365
DL-tetrahydronicotyrine
Destruxol
Destruxol Orchid Spray
EINECS 200-193-3
ENT 3,424
EPA Pesticide Chemical Code 056702
Emo-Nik
Flux Maag
Fumeto bac
Fumetobac
HSDB 1107
Habitrol
Habitrol (TN)
L(-)-nicotine
L-3-(1-Methyl-2-pyrrolidyl)pyridine
 
L-Nicotine
LS-202
MLS001055457
MLS001335905
Mach-Nic
Methyl-2-pyrrolidinyl)pyridine
Micotine
MolPort-000-744-731
N3876_SIGMA
N5511_FLUKA
N5511_SIGMA
NCGC00090693-01
NCGC00090693-02
NCGC00090693-03
NCGC00090693-04
NCGC00090693-05
NCGC00090693-06
NCGC00090693-07
NCT
NICOTINE AND SALTS
NSC 5065
NSC97238
Niagara P.A. Dust
Nic-Sal
Nico-Dust
Nico-Fume
Nicocide
Nicoderm
Nicoderm Cq
Nicoderm Patch
Nicorette
Nicorette Plus
Nicotin
Nicotina
Nicotina [Italian]
Nicotine
Nicotine (USP)
Nicotine (compounds related to)
Nicotine Alkaloid
Nicotine Patch
Nicotine Polacrilex
Nicotine [BSI:ISO]
Nicotine [UN1654]
Nicotine [UN1654] [Poison]
Nicotine [USAN]
Nicotrol
Nicotrol Inhaler
Nicotrol Ns
Nictoine patch
Nikotin
Nikotin [German]
Nikotyna
Nikotyna [Polish]
Ortho N-4 Dust
Ortho N-5 Dust
PDSP1_000113
PDSP1_000465
PDSP2_000463
PDSP2_000555
Prostep
R)-(+)-Nicotine
RCRA waste no. P075
RCRA waste number P075
SAM002564224
SDCCGMLS-0066911.P001
SMR000059074
Tendust
Transdermal Nicotine
UN1654
a -N-Methylpyrrolidine
a-N-Methylpyrrolidine
alpha-N-Methylpyrrolidine
beta-Pyridyl-alpha-N-methyl pyrrolidine
beta-Pyridyl-alpha-N-methylpyrrolidine
bmse000105
delta-Nicotine
nicotine
nicotine replacement patch
17
DopaminePhase 4, Phase 3, Phase 2, Phase 1, Phase 0367851-61-6, 62-31-7681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
KBio1_000780
 
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
18
GalantaminePhase 4104357-70-09651, 908828, 9651
Synonyms:
(-)-Galanthamine
(4aS,6R,8aS)-4a,5,9,10,11,12-Hexahydro-3-methoxy-11-methyl-6H-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol
1551-02-6
1953-04-4
1dx6
1qti
357-70-0
4-27-00-02184 (Beilstein Handbook Reference)
736-79-8
AC-20240
AC1L1TIM
BIDD:GT0517
BPBio1_000480
BRD-K49481516-004-03-5
BRD-K49481516-004-04-3
BRN 0093736
BSPBio_000436
BSPBio_003416
C08526
CHEBI:42944
CHEMBL659
CID9651
D04292
DivK1c_000590
GNT
Galantamin
Galantamina
Galantamina [INN-Spanish]
Galantamine
Galantamine (USAN/INN)
Galantamine [USAN:INN]
Galantaminum
Galantaminum [INN-Latin]
Galanthamine
Galanthamine hydrobromide
Galanthaminum
 
HMS2089H03
HSDB 7361
IDI1_000590
InChI=1/C17H21NO3/c1-18-8-7-17-6-5-12(19)9-14(17)21-16-13(20-2)4-3-11(10-18)15(16)17/h3-6,12,14,19H,7-10H2,1-2H3/t12-,14-,17-/m0/s1
Jilkon
KBio1_000590
KBio2_001751
KBio2_004319
KBio2_006887
KBio3_002636
KBioGR_001417
KBioSS_001751
LS-71039
Lycoremin
Lycoremine
MolPort-002-521-885
NCGC00024731-02
NINDS_000590
NSC 100058
Prestwick0_000588
Prestwick1_000588
Prestwick2_000588
Prestwick3_000588
Probes1_000055
Probes2_000395
Razadyne ER
Reminyl
Reminyl (TN)
SDCCGMLS-0066737.P001
SMP1_000131
SPBio_002655
STOCK1N-46108
Spectrum3_001738
Spectrum4_000839
Spectrum5_001673
Spectrum_001271
UNII-0D3Q044KCA
galanthamine
19OpicaponePhase 4, Phase 3, Phase 2, Phase 133923287-50-7
20
modafinilPhase 419568693-11-84236
Synonyms:
Dea No. 1680
Modafinil
Modafinil [USAN:INN]
Modafinil [Usan:Inn]
Modafinilo
Modafinilo [Spanish]
 
Modafinilum
Modafinilum [Latin]
Moderateafinil
Modiodal
Provigil
Sparlon
modafinil
21
ArmodafinilPhase 4195112111-43-0
Synonyms:
 
(–)-2-[(R)-(diphenylmethyl)sulfinyl]acetamide
R-modafinil
22
TrandolaprilPhase 42187679-37-65484727
Synonyms:
(2S,3aR,7aS)-1-((S)-N-((S)-1-Carboxy-3-phenylpropyl)alanyl)hexahydro-2-indolinecarboxylic acid, 1-ethyl ester
(2S,3aR,7aS)-1-(N-((1S)-1-((Ethyloxy)carbonyl)-3-phenylpropyl)-L-alanyl)octahydro-1H-indole-2-carboxylic Acid
(2S,3aR,7aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid
1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydro-1H-indol-2-carboxylic acid
87679-37-6
AC1NUNSR
BIDD:GT0804
C24H34N2O5
CCRIS 6594
CHEMBL1519
CID5484727
D00383
DB00519
FT-0082544
Gopten
I06-1849
 
LS-82763
Mavik
Mavik (TN)
NCGC00182079-03
Odric
Odrik
Preran
RU 44570
RU-44570
RU44570
Tarka
Trandolapril (JAN/INN)
Trandolapril [INN:BAN]
Trandolaprilum
Trandolaprilum [Latin]
UNII-1T0N3G9CRC
Udrik
trandolapril
23
protease inhibitorsPhase 45157
Synonyms:
 
protease inhibitors
24
verapamilPhase 412352-53-92520
Synonyms:
(+-)-Verapamil
(+/-)-VERAPAMIL
(1)-3-(3,4-Dimethoxyphenyl)-6-((5,6-dimethoxyphenethyl)methylamino)hexane-3-carbonitrile
2-(3,4-Dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methyl-amino]-2-(1-methylethyl) pentanenitrile
2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]-2-propan-2-ylpentanenitrile
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile
5-((3,4-Dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile
5-[(3,4-Dimethoxyphenethyl)methylamino]-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile
52-53-9
56949-77-0
AB00053495
AC-16016
AC1L1DV5
Akilen
Anpec
Apo-Verap
Arpamyl
Arpamyl LP
BPBio1_000268
BRD-A09533288-001-02-7
BRD-A09533288-003-05-6
BSPBio_000242
BSPBio_001513
BSPBio_002358
Berkatens
Bio-0754
Bio1_000425
Bio1_000914
Bio1_001403
Bio2_000233
Bio2_000713
C07188
C27H38N2O4
CCRIS 6749
CHEBI:9948
CHEMBL6966
CID2520
CP-16533-1
CP-165331
Calan
Calan SR
Calan sr
Calaptin
Calaptin 240 SR
Calcan
Cardiabeltin
Cardiagutt
Cardibeltin
Cardioprotect
Caveril
Civicor
Civicor Retard
Coraver
Cordilox
Cordilox SR
Corpamil
Covera-HS
Covera-Hs
Covera-hs
D-365
D02356
DB00661
Dexverapamil
Dignover
Dilacoran
Dilacoran HTA
DivK1c_000399
Drosteakard
Durasoptin
EINECS 200-145-1
EINECS 260-462-6
Elthon
FT-0080127
Falicard
Finoptin
Flamon
Geangin
HMS1791L15
HMS1989L15
HMS2089H17
Harteze
Hexasoptin
Hexasoptin Retard
Hormitol
I06-0063
IDI1_000399
IDI1_033983
Ikacor
Ikapress
Inselon
Iproveratril
Isoptimo
Isoptin
Isoptin Retard
Isoptin SR
Isoptin sr
Isoptine
Isoptino
Isotopin
Izoptin
Jenapamil
KBio1_000399
KBio2_000233
KBio2_002343
KBio2_002801
KBio2_004911
KBio2_005369
KBio2_007479
KBio3_000465
KBio3_000466
 
KBio3_002823
KBioGR_000233
KBioGR_001372
KBioGR_002343
KBioSS_000233
KBioSS_002346
L001330
LS-174
Lekoptin
Lodixal
Lopac0_001237
Magotiron
Manidon
Manidon Retard
MolPort-000-721-258
NCGC00016083-14
NCGC00024710-04
NCGC00024710-05
NCGC00024710-06
NCGC00024710-07
NCGC00024710-08
NCGC00024710-09
NCI60_020143
NINDS_000399
NSC272366
NU-Verap
Novapamyl LP
Novo-Veramil
Nu-Verap
Ormil
Praecicor
Prestwick0_000141
Prestwick1_000141
Prestwick2_000141
Prestwick3_000141
Quasar
Rapam
Robatelan
SPBio_001820
SPBio_002181
STK538085
Securon
Spectrum2_001740
Spectrum4_000906
Spectrum5_001786
Tarka
UNII-CJ0O37KU29
Univer
Univex
VERAPAMIL
Vasolan
Vasomil
Vasopten
Vera-Sanorania
Verabeta
Veracaps SR
Veracim
Veracor
Verahexal
Veraloc
Veramex
Veramil
Verapamil
Verapamil (USAN/INN)
Verapamil AL
Verapamil Acis
Verapamil Atid
Verapamil Basics
Verapamil Ebewe
Verapamil HCl
Verapamil Henning
Verapamil Injection
Verapamil MSD
Verapamil NM
Verapamil NM Pharma
Verapamil Nordic
Verapamil PB
Verapamil Riker
Verapamil SR
Verapamil Verla
Verapamil [USAN:BAN:INN]
Verapamil [USAN:INN:BAN]
Verapamil [Usan:Ban:Inn]
Verapamil-AbZ
Verapamilo
Verapamilo [INN-Spanish]
Verapamilum
Verapamilum [INN-Latin]
Verapin
Verapress 240 SR
Veraptin
Verasal
Verasifar
Veratensin
Verdilac
Verelan
Verelan PM
Verelan SR
Verexamil
Veroptinstada
Verpamil
Vetrimil
Vortac
Vérapamil
alpha-((N-Methyl-N-homoveratryl)-gamma-aminopropyl)-3,4-dimethoxyphenylacetonitrile
alpha-(3-((2-(3,4-Dimethoxyphenyl)ethyl)-methylamino)propyl)-3,4-dimethoxy-alpha-(1-methylethyl)benzeneacetonitrile
alpha-Isopropyl-alpha-((N-methyl-N-homoveratryl)-gamma-aminopropyl)-3,4-dimethoxyphenylacetonitrile
cMAP_000023
delta-365
nchembio.368-comp2
nchembio.79-comp5
25
MidodrinePhase 442133163-28-7, 42794-76-34195
Synonyms:
( -)-Midodrin hydrochloride
( -)-Midodrine hydrochloride
()-1-(2,5-Dimethoxyphenyl)-2-glycinamidoethanol
(+-)-1-(2',5'-Dimethoxyphenyl)-2-glycinamidoethanol hydrochloride
(+-)-2-Amino-N-(beta-hydroxy-2,5-dimethoxyphenethyl)acetamide monohydrochloride
(+-)-2-amino-N-(beta-hydroxy-2,5-dimethoxyphenethyl)acetamide
(+-)-Midodrine hydrochloride
(+/-)-1-(2,5-Dimethoxyphenyl)-2-glycinamidoethanol
(RS)-N'-(beta-Hydroxy-2,5-dimethoxy-phenethyl)glycinamid
1-(2',5'-Dimethoxyphenyl)-2-glycinamidoethanol
1-(2',5'-Dimethoxyphenyl)-2-glycinamidoethanol hydrochloride
2-Amino-N-(2,5-dimethoxy-beta-hydroxyphenethyl)acetamid
2-Amino-N-(2,5-dimethoxy-beta-hydroxyphenethyl)acetamide
2-Amino-N-(2,5-dimethoxy-beta-hydroxyphenethylacetamide
2-Amino-N-(2-(2,5-dimethoxyphenyl)-2-hydroxyethyl)acetamide monohydrochloride
2-Amino-N-(2-(2,5-dimethoxyphenyl)-2-hyyroxyethyl)acetamide monohydrochloride
2-amino-N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide
2-amino-N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide hydrochloride
3092-17-9
3092-17-9 (mono-hydrochloride)
42794-76-3
42794-76-3 (Parent)
43218-56-0
97476-58-9
A 4020 Linz
A-4020 Linz
AB00053715
AC1L1HMJ
AC1L2BU9
Acetamide, 2-amino-N-(2-(2,5-dimethoxyphenyl)-2-hydroxyethyl)-, monohydrochloride
Acetamide, 2-amino-N-(beta-hydroxy-2,5-dimethoxyphenethyl)-, hydrochloride
Alphamine
Amatine
BPBio1_000157
BRD-A79981887-003-05-7
BSPBio_000141
BSPBio_003150
C07890
C12H18N2O4
C12H18N2O4.HCl
CHEBI:31847
CHEBI:6933
CHEMBL1200461
CID18340
CID4195
CPD000058833
D01307
D08220
DB00211
DL-N1-(beta-Hydroxy-2,5-dimethoxyphenethyl)glycinamid
DivK1c_000955
EINECS 255-945-3
EINECS 256-148-3
Gutron
HMS1568H03
HMS1922O03
Hipertan
I06-0865
IDI1_000955
KBio1_000955
KBio2_002121
KBio2_004689
KBio2_007257
 
KBio3_002650
KBioGR_000763
KBioSS_002121
LS-174957
LS-8042
LS-8052
M8277_FLUKA
M8277_SIGMA
MIDODRINE HYDROCHLORIDE
MLS001332567
MLS001332568
MLS002154233
Metligene
Midamine
Midodrin
Midodrina
Midodrina [INN-Spanish]
Midodrine (INN)
Midodrine HCL
Midodrine Monohydrochloride
Midodrine [BAN:INN]
Midodrine [INN:BAN]
Midodrine hydrochloride
Midodrine hydrochloride (JAN/USAN)
Midodrine hydrochloride [USAN:JAN]
Midodrine hydrochloride [USAN]
Midodrinum
Midodrinum [INN-Latin]
MolPort-003-666-473
MolPort-003-849-221
N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]glycinamide
N-{2-[2,5-bis(methyloxy)phenyl]-2-hydroxyethyl}glycinamide
NCGC00095311-01
NCGC00178238-01
NCGC00178238-02
NINDS_000955
Prestwick0_000191
Prestwick1_000191
Prestwick2_000191
Prestwick3_000191
Prestwick_625
Pro-Amatine
Pro-Amatine (TN)
ProAmatine
SAM002564219
SBB066174
SMR000058833
SPBio_001390
SPBio_002062
SPECTRUM1503257
ST-1085
Spectrum2_001545
Spectrum3_001585
Spectrum4_000192
Spectrum5_000962
Spectrum_001641
St 1085
St. Peter 224
TL8002369
TS 701
UNII-59JV96YTXV
UNII-6YE7PBM15H
[+/-]-1-[2,5-Dimethoxyphenyl]-2-glycinamidoethanol
midodrine
26Lithium carbonatePhase 4, Phase 1, Phase 2222554-13-2
27
PergolidePhase 4, Phase 31266104-22-147811
Synonyms:
(6aR,9R,10aR)-9-(Methylthiomethyl)-7-propyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline
(8beta)-8-[(methylsulfanyl)methyl]-6-propylergoline
(8beta)-8-[(methylthio)methyl]-6-propylergoline
66104-22-1
66104-23-2 (mesylate)
AC1L2IT3
AC1Q7DT2
BIDD:GT0177
BPBio1_000254
BPBio1_001211
BRD-K60770992-001-01-8
BRD-K60770992-066-05-2
BSPBio_000230
BSPBio_003156
Biomol-NT_000025
C07425
C19H26N2S
CHEBI:112494
CHEMBL531
CID47811
D08339
DB01186
DivK1c_000442
HMS2089C18
IDI1_000442
InChI=1/C19H26N2S/c1-3-7-21-11-13(12-22-2)8-16-15-5-4-6-17-19(15)14(10-20-17)9-18(16)21/h4-6,10,13,16,18,20H,3,7-9,11-12H2,1-2H3/t13-,16-,18-/m1/s
KBio1_000442
KBio2_002127
KBio2_004695
KBio2_007263
KBio3_002656
KBioGR_001409
KBioSS_002127
 
LS-64479
LY-127,809
Lopac0_000984
MolPort-003-849-834
NCGC00017366-05
NCGC00142538-01
NCGC00142538-02
NCGC00142538-03
NINDS_000442
Pergolida
Pergolida [INN-Spanish]
Pergolide (INN)
Pergolide Mesylate
Pergolide Methanesulfonate
Pergolide [INN:BAN]
Pergolidum
Pergolidum [INN-Latin]
Permax
Permax (TN)
Prestwick0_000295
Prestwick1_000295
Prestwick2_000295
Prestwick3_000295
SPBio_002099
SPBio_002449
ST057534
Spectrum2_001970
Spectrum3_001588
Spectrum4_000835
Spectrum5_001649
Spectrum_001647
UNII-24MJ822NZ9
nchembio873-comp45
pergolide
28
AtenololPhase 49929122-68-72249
Synonyms:
( inverted question mark)-Atenolol
(+-)-4-(2-Hydroxy-3-isopropylaminopropoxy)phenylacetamide
(+-)-Atenolol
(+/-)-4-[2-Hydroxy-3-[(1-methylethyl)amino]propoxy]benzeneacetamide
(1)-2-(4-(2-Hydroxy-3-(isopropylamino)propoxy)phenyl)acetamide
(?)-Atenolol
1-p-Carbamoylmethylphenoxy-3-isopropylamino-2-propanol
2-(4-(2-Hydroxy-3-isopropylaminopropoxy)phenyl)acetamid
2-(4-{2-hydroxy-3-[(propan-2-yl)amino]propoxy}phenyl)acetamide
2-(p-(2-Hydroxy-3-(isopropylamino)propoxy)phenyl)acetamide
2-[4-(2-Hydroxy-3-isopropylaminopropoxy)phenyl]acetamide
2-[4-({2-hydroxy-3-[(1-methylethyl)amino]propyl}oxy)phenyl]acetamide
2-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetamide
2-{4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}acetamide
29122-68-7
4-(2-Hydroxy-3-((1-methylethyl)amino)propoxy)benzeneacetamide
4-[2 -Hydroxy-3 -(isopropylamino)-propoxy]phenylacetamide
4-[2'-Hydroxy-3'-(isopropylamino)propoxy]phenylacetamide
60966-51-0
A 7655
A7655_SIGMA
AC-11142
AC1L1D99
AC1Q1QBX
AKOS005111050
ARONIS23884
Acetamide,2-(p-(2-hydroxy-3-(isopropylamino)propoxy)phenyl)
Aircrit
Alinor
Altol
Anselol
Antipressan
Apo-Atenolol
Atcardil
Atecard
Atehexal
Atenblock
Atendol
Atenet
Ateni
Atenil
Atenol
Atenol 1A Pharma
Atenol 1A pharma
Atenol AL
Atenol Acis
Atenol Atid
Atenol CT
Atenol Cophar
Atenol Fecofar
Atenol GNR
Atenol Gador
Atenol Genericon
Atenol Heumann
Atenol MSD
Atenol NM Pharma
Atenol Nordic
Atenol PB
Atenol Quesada
Atenol Stada
Atenol Tika
Atenol Trom
Atenol Von CT
Atenol acis
Atenol ct
Atenol von ct
Atenol-Mepha
Atenol-Ratiopharm
Atenol-Wolff
Atenol-ratiopharm
Atenolin
Atenolol (JAN/USP)
Atenolol (JP15/USP/INN)
Atenolol [USAN:BAN:INN:JAN]
Atenolol [USAN:INN:BAN:JAN]
Atenololum
Atenololum [INN-Latin]
Atenomel
Atereal
Aterol
BB_SC-1519
BIM-0050109.0001
BRD-A20239487-001-02-5
BRN 2739235
BSPBio_002915
Betablok
Betacard
Betasyn
Betatop GE
Betatop Ge
Blocotenol
Blokium
CCRIS 4196
CHEBI:2904
CHEMBL24
CID2249
CPD000036768
Cardaxen
Cardiopress
Corotenol
Cuxanorm
D001262
D00235
DB00335
DivK1c_000057
Duraatenolol
Duratenol
 
EINECS 249-451-7
EINECS 262-544-7
EU-0100121
Evitocor
Farnormin
Felo-Bits
HMS1569L13
HMS1921H09
HMS2090I19
HMS2092D19
HMS500C19
HSDB 6526
Hipres
Hypoten
I01-3572
ICI 66,082
ICI 66082
ICI-66082
ICI66082
IDI1_000057
Ibinolo
InChI=1/C14H22N2O3/c1-10(2)16-8-12(17)9-19-13-5-3-11(4-6-13)7-14(15)18/h3-6,10,12,16-17H,7-9H2,1-2H3,(H2,15,18)
Internolol
Jenatenol
Juvental
KBio1_000057
KBio2_001844
KBio2_004412
KBio2_006980
KBio3_002415
KBioGR_000790
KBioSS_001844
L000116
LS-28557
LS-9707
Lo-Ten
Lo-ten
Lopac0_000121
Loten
Lotenal
MLS000069622
MLS001066372
MLS001074163
MLS001304038
MolPort-001-792-717
Myocord
NCGC00015007-07
NCGC00015007-13
NCGC00024566-03
NCGC00024566-04
NCGC00024566-05
NCGC00024566-06
NCGC00024566-07
NINDS_000057
Neatenol
Normalol
Normiten
Noten
Oprea1_448775
Oraday
Ormidol
Panapres
Plenacor
Premorine
Prenolol
Prenormine
Prinorm
SAM002564193
SMR000036768
SPBio_001482
SPECTRUM1501127
STK528649
Scheinpharm Atenol
Seles Beta
Seles beta
Selobloc
Serten
Servitenol
Spectrum2_001411
Spectrum3_001448
Spectrum4_000435
Spectrum5_001509
Spectrum_001364
Stermin
Tenidon
Teno-Basan
Teno-basan
Tenobloc
Tenoblock
Tenolol
Tenoprin
Tenoretic
Tenormin
Tenormin (TN)
Tenormine
Tenormine [French]
Tensimin
Tensotin
Tredol
UNII-50VV3VW0TI
Unibloc
Uniloc
Vascoten
Vericordin
Wesipin
Xaten
atenolol
benzeneacetamide, 4-[2'-hydroxy-3
duratenol
29
ApomorphinePhase 4, Phase 3, Phase 23541372-20-7, 58-00-46005
Synonyms:
(-)-10,11-Dihydroxyaporphine
(6AR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol
(6aR)-5,6,6a,7-Tetrahydro-6-methyl-4H-dibenzo(de,g)chinolin-10,11-diol
(6aR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol
(R)-5,6,6a,7-Tetrahydro-6-methyl-4H-dibenzo[de,g]quinoline-10,11-diol
(R)-5,6,6a,7-tetrahydro-6-methyl-4H-dibenzo[de,g]quinoline-10,11-diol
(R)-6-Methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol
(−)-10,11-dihydroxyaporphine
314-19-2 (hydrochloride anhydrous)
41372-20-7 (hydrochloride hemihydrate)
4H-Dibenzo(de,g)quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, (R)- (9CI)
4H-Dibenzo(de,g)quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, HCl, (R)-, hemihydrate
58-00-4
6a-beta-Aporphine-10,11-diol
6a-beta-Aporphine-10,11-diol, hydrochloride, hemihydrate
6abeta-Aporphine-10,11-diol
AC1L1LLC
Apokyn
Apomorfin
Apomorphin
Apomorphine (BAN)
Apomorphine HCl hydrate
Apomorphine Hydrochloride Hemihydrate
Apomorphine hydrochloride
Apomorphine hydrochloride hemihydrate
Apomorphinium Chloride Hemihydrate
Apomorphinium chloride hemihydrate
Apormorphine
BPBio1_000092
BPBio1_001179
BRD-K76022557-001-01-3
BSPBio_000082
Biomol-NT_000019
C17H17NO2
 
CE0800000
CHEBI:48538
CID6005
D07460
DB00714
EINECS 200-360-0
HMS2089C10
HSDB 3289
IV Apomorphine
Ixense
L-Apomorphine
LS-21474
NCGC00025349-01
NCGC00025349-02
NIOSH/CE0800000
PDSP1_000780
PDSP2_001488
Prestwick0_000101
Prestwick1_000101
Prestwick2_000101
Prestwick3_000101
R-(-)-Apomorphine
R-(−)-apomorphine
SMP1_000027
SPBio_002021
STOCK1N-03149
Tocris-2073
UNII-N21FAR7B4S
Uprima
Uprima (TN)
VR-040
VR-400
VR004
apomorphine
nchembio.307-comp3
nchembio873-comp6
30
CabergolinePhase 4, Phase 34681409-90-754746
Synonyms:
(8R)-6-Allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide
(8R)-6-allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide
(8beta)-N-[3-(dimethylamino)Propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide
(8beta)-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-6-(prop-2-en-1-yl)ergoline-8-carboxamide
(8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide
(8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-prop-2-en-1-ylergoline-8-carboxamide
1-((6-Allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea
1-Ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'beta-carbonyl)urea
1-[(6-Allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea
1-[(6-allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea
1-ethyl-2-(3'-dimethylaminopropyl)-3-(6'-allylergoline-8'-beta-carbonyl)urea diphosphate
1-ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'beta-carbonyl)urea
81409-90-7
85329-89-1 (diphosphate)
AC-14150
AC1L1HO0
AC1Q5OQ0
BIDD:GT0775
BRD-K86882815-001-01-6
BRN 6020775
C08187
C26H37N5O2
CG-101
CHEBI:3286
 
CHEMBL1201087
CID54746
Cabaser
Cabaser (TN)
Cabaseril
Cabergolina
Cabergolina [Spanish]
Cabergoline
Cabergoline (JAN/USAN/INN)
Cabergoline [USAN:BAN:INN]
Cabergolinum
Cabergolinum [Latin]
D00987
DB00248
Dostinex
Dostinex (TN)
FCE-21336
FT-0081285
Galastop
HMS2090A09
LS-64370
MolPort-003-845-557
Sogilen
UNII-LL60K9J05T
cabergoline
31
TrimethobenzamidePhase 4, Phase 16138-56-75577
Synonyms:
N-[[4-(2-Dimethylaminoethoxy)phenyl]methyl]-3,4,5-trimethoxybenzamide
Trimethobenzamidum
 
Trimethobenzamidum [INN-Latin]
Trimetobenzamida
Trimetobenzamida [INN-Spanish]
32
SelegilinePhase 4, Phase 22714611-51-926757, 5195
Synonyms:
(-)-(N)-Methyl-N-((1R)-1-methyl-2-phenylethyl)prop-2-yn-1-amine
(-)-Deprenil
(2R)-N-methyl-1-phenyl-N-prop-2-ynylpropan-2-amine
(R)-(-)-N,alpha-Dimethyl-N-2-propinylphenethylamine
(R)-(-)-N-Methyl-N-(1-phenyl-2-propyl)-2-propinylamin
(−)-selegiline
14611-51-9
14611-52-0 (hydrochloride)
2079-54-1 (deprenyl.hydrochloride)
AC1L1BTZ
AC1Q2860
AKOS000281115
Anipryl
Apo-Selegiline
BPBio1_000687
BRD-K86434416-001-02-7
BRD-K86434416-003-03-1
BSPBio_000623
BSPBio_001589
C07245
C13H17N
CHEBI:9086
CHEMBL972
CID26757
Carbex
D03731
DB01037
Deprenyl
Eldepryl
Emsam
Emsam (TN)
Gen-Selegiline
HMS1791P11
HMS1989P11
HMS2089D09
Humex
 
Jumex
L-Deprenalin
L-Deprenyl
LS-30156
MolPort-000-883-771
N-methyl-N-[(1R)-1-methyl-2-phenylethyl]prop-2-yn-1-amine
N-methyl-N-[(2R)-1-phenylpropan-2-yl]prop-2-yn-1-amine
NCGC00024994-01
NCGC00024994-02
NCGC00024994-03
NCGC00024994-04
Novo-Selegiline
Nu-Selegiline
Prestwick0_000552
Prestwick1_000552
Prestwick2_000552
Prestwick3_000552
SPBio_002544
STK640578
Sd Deprenyl
Selegeline Hcl
Selegilina
Selegilina [INN-Spanish]
Selegiline (USAN/INN)
Selegiline Transdermal System (STS) patch
Selegiline [INN:BAN]
Selegiline, (R)-Isomer
Selegilinum
Selegilinum [INN-Latin]
Selegyline
Tocris-1095
UNII-2K1V7GP655
Yumex
ZINC19632633
Zelapar
l-E 250
selegiline
33
MemantinePhase 4, Phase 217619982-08-24054
Synonyms:
1,3-Dimethyl-5-adamantanamine
1-Amino-3,5-dimethyladamantane
19982-08-2
3,5-Dimethyl-1-adamantanamine
3,5-Dimethyl-1-adamantylamine
3,5-Dimethyl-1-aminoadamantane
3,5-Dimethyladamantan-1-ylamine
3,5-Dimethyltricyclo(3.3.1.1(3,7))decan-1-amine
3,5-dimethyladamantan-1-amine
3,5-dimethyltricyclo[3.3.1.1~3,7~]decan-1-amine
41100-52-1 (Hydrochloride)
51052-62-1
AB00053600
AC1L1HB7
AKOS000113995
BBL000737
BPBio1_001117
BPBio1_001270
BSPBio_001015
Biomol-NT_000209
C13736
CBMicro_020348
CHEBI:152523
CHEMBL807
CID4054
D08174
DB01043
DMAA
DivK1c_000068
EU-0053634
Ebixa
Exiba
Exiba (TN)
HMS500D10
HSDB 7327
IDI1_000068
KBio1_000068
KBio2_001087
KBio2_003655
 
KBio2_006223
KBio3_001926
KBioGR_001543
KBioSS_001087
LS-157051
Lopac0_000861
Memantin
Memantina
Memantina [INN-Spanish]
Memantine
Memantine (INN)
Memantine HCL
Memantine Hydrochloride
Memantine [INN:BAN]
Memantine [INN]
Memantinum
Memantinum [INN-Latin]
MolPort-002-041-858
NCGC00015705-05
NCGC00024782-02
NCGC00024782-03
NINDS_000068
Namenda
Oprea1_480562
Prestwick0_000978
Prestwick1_000978
Prestwick2_000978
Prestwick3_000978
SPBio_001456
SPBio_002926
ST057652
STK520682
Spectrum2_001408
Spectrum3_000923
Spectrum4_001022
Spectrum5_001355
Spectrum_000607
UNII-W8O17SJF3T
ZERO/006024
memantine
34
PramipexolePhase 4, Phase 3, Phase 2, Phase 1137104632-26-059868, 119570
Synonyms:
(-)-Pramipexole
(6S)-6-N-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
(6S)-N(6)-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
(6S)-N6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
(S)-2-Amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole
(S)-N  6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
104632-26-0
111GE001
2-amino-4,5,6,7-tetrahydro-6-propylaminobenzothiazole
2-amino-6-propylaminotetrahydrobenzothiazole
AC1L3P1T
BIDD:GT0250
C10H17N3S
CHEBI:8356
CHEMBL301265
CID119570
CPD000449298
D05575
DivK1c_006916
Furfuryl Acetate
HMS2051A21
HMS2090C15
KBio1_001860
KBio2_002340
KBio2_004908
 
KBio2_007476
KBioSS_002343
LS-40722
MLS000758250
MLS001423952
Mirapex
MolPort-003-849-957
NCGC00167441-01
Pramipexol
Pramipexol [Spanish]
Pramipexole
Pramipexole (USAN/INN)
Pramipexole 2HCl Monohydrate
Pramipexole [USAN:INN]
Pramipexole hydrochloride
Pramipexolum
Pramipexolum [Latin]
SAM001247006
SBB070477
SMR000449298
SND-919
SUD919CL2Y
SpecPlus_000820
Spectrum5_001453
Spectrum_001838
U-98528E
pramipexole
35Solifenacin succinatePhase 4110242478-38-2
36
EntacaponePhase 4, Phase 3, Phase 2, Phase 149130929-57-65281081
Synonyms:
(2E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide
(E)-2-Cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-2-propenamide
(E)-2-cyano-3-(3,4-dihydroxy-5-nitro-phenyl)-N,N-diethyl-prop-2-enamide
(E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide
(E)-alpha-Cyano-N,N-diethyl-3,4-dihydroxy-5-nitrocinnamamide
(e)-alpha-Cyano-N,N-diethyl-3,4-dihydroxy-5-nitrocinnamamide
116314-67-1
130929-57-6
2-Cyano-N,N-diethyl-3-(3,4-dihydroxy-5-nitrophenyl)propenamide
AC-393
AC1NQY02
BIDD:GT0026
C071192
C07943
C14H15N3O5
CHEBI:4798
CHEMBL953
CID5281081
COM-998
Comtan
Comtan (TN)
Comtess
D00781
 
DB00494
ENTACAPONE
Entacapona
Entacapona [INN-Spanish]
Entacapone
Entacapone (JAN/USAN/INN)
Entacapone [USAN:INN]
Entacapone [Usan:Inn]
Entacaponum
Entacaponum [INN-Latin]
HMS2089O16
KB475572
LS-123327
LS-172316
MolPort-003-847-054
N,N-Diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl) acrylamide
N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl) acrylamide
NCGC00164555-01
Novartis brand of entacapone
OR 611
OR-611
Orion brand of entacapone
UNII-4975G9NM6T
entacapone
37
RasagilinePhase 4, Phase 3, Phase 2, Phase 154136236-51-63052776
Synonyms:
(1R)-N-(prop-2-yn-1-yl)-2,3-dihydro-1H-inden-1-amine
(1R)-N-Propargylindan-1-amine
(1R)-N-prop-2-ynyl-2,3-dihydro-1H-inden-1-amine
(R)-Indan-1-yl-prop-2-ynyl-amine
(R)-N-2-Propynyl-1-indanamine
136236-51-6
1H-Inden-1-amine, 2,3-dihydro-N-2-propynyl-, (1R)
AC-723
AC1MHJZT
Azilect
Azilect (TN)
CHEBI:45357
 
CHEMBL887
CID3052776
D08469
DB01367
LS-186771
LS-187776
MolPort-003-850-132
NCGC00168774-01
RAS
Rasagiline (INN)
Rasagiline [INN]
UNII-003N66TS6T
ZINC19875504
rasagiline
38
CarbidopaPhase 4, Phase 3, Phase 2, Phase 117028860-95-934359, 38101
Synonyms:
(-)-L-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid
(-)-L-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid monohydrate
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazino-2-methylpropanoic acid
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid hydrate
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid monohydrate
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid--water (1/1)
(S)-(-)-carbidopa
(S)-(-)-carbidopa hydrate
(S)-(−)-carbidopa
(S)-alpha--Hydrazino-3,4-dihydroxy-alpha--methyl-benzenepropanoic acid monohydrate
(S)-carbidopa
(S)-carbidopa hydrate
(alphaS)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid
(alphaS)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid monohydrate
(αS)-α-hydrazino-3,4-dihydroxy-α-methylbenzenepropanoic acid
27925-91-3
28860-95-9
31823-41-3
38821-49-7
AC-1676
AC1L1RFR
AC1L1Z32
AC1Q5QGW
Atamet
BB_SC-5095
Benzenepropanoic acid, alpha-hydrazino-3,4-dihydroxy-alpha-methyl-, monohydrate, (S)
C-126
C-DOPA
C126_SIGMA
C1335_SIGMA
CCRIS 5093
CHEBI:3395
CHEBI:39585
CHEMBL1200748
CHEMBL1201236
CID34359
CID38101
CPD-11550
Carbidopa (anhydrous)
Carbidopa Anhydrous
Carbidopa Monohydrate
Carbidopa [USAN:INN:BAN]
Carbidopa anhydrous
Carbidopa hydrate
Carbidopa, (S)-Isomer
Carbidopa, Entacapone, & Levodopa
Carbidopa-1-wasser
 
Carbidopum
Carbidopum [INN-Latin]
DB00190
EINECS 249-271-9
EU-0100382
HMS2089B12
Hadrazino-alpha-methyldopa
Hydrocinnamic acid, (-)-L-alpha-hydrazino-3,4-dihydroxy-alpha-methyl-, monohydrate
KINSON, 3-(3,4-DIHYDROXY-PHENYL)-2-HYDRAZINO-2-METHYL-PROPIONIC ACID
L-3-(3,4-Dihydroxyphenyl)-2-methyl-2-hydrazinopropionic acid
L-3-(3,4-dihydroxyphenyl)-2-methyl-2-hydrazinopropionic acid
L-alpha-(3,4-dihydroxybenzyl)-alpha-hydrazinopropionic acid monohydrate
L-alpha-Methyl-alpha-hydrazino-beta-(3,4-dihydroxyphenylpropionic acid
L-alpha-Methyl-beta-(3,4-dihydroxyphenyl)-alpha-hydrazinopropionic acid
L-alpha-Methyldopahydrazine
L-α-methyldopahydrazine
LS-77199
Lodosin
Lodosyn
Lodosyn, Carbidopa
Lopac0_000382
MK 486
MK-485
MK-486
MLS000069628
MLS002207014
Methyldopahydrazine
MolPort-003-940-629
MolPort-005-934-181
N-Aminomethyldopa
NCGC00024596-01
NCGC00024596-03
NCGC00024596-05
NCGC00024596-06
S(-)-CARBIDOPA
S(-)-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid monohydrate
S-(-)-Carbidopa
S-(-)-alpha-Hydrazino-3,4-dihydroxy-2-methylbenzenepropanoic acid
S1891_Selleck
SMP1_000057
SMR000058235
ST055523
Stalevo
Tocris-0455
UNII-KR87B45RGH
UNII-MNX7R8C5VO
alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid
alpha-Methyldopahydrazine
carbidopa
carbidopum monohydricum
39
RivastigminePhase 4, Phase 382123441-03-277991
Synonyms:
(S)-3-(1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate
123441-03-2
3-((1S)-1-(Dimethylamino)ethyl)phenyl N-ethyl-N-methylcarbamate
3-((1S)-1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate
3-[(1S)-1-(dimethylamino)ethyl]phenyl ethyl(methyl)carbamate
AB1004572
AC1L2U92
BIDD:GT0316
C11766
CHEMBL636
CID77991
Carbamic acid, N-ethyl-N-methyl-, 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester
Carbamic acid, ethylmethyl-, 3-((1S)-1-(dimethylamino)ethyl)phenyl ester
D03822
DB00989
ENA 713 free base
 
Ena 713 Free Base
Ethylmethylcarbamic acid 3-((1S)-1-(dimethylamino)ethyl)phenyl ester
Exelon
Exelon Patch
HMS2089H18
I06-2037
LS-172571
MolPort-003-666-662
NCGC00167531-01
Rivastigmine (JAN/USAN/INN)
Rivastigmine Hydrogen Tartrate
Rivastigmine [USAN:INN]
Rivastigmine hydrogen tartrate
SDZ 212-713
UNII-PKI06M3IW0
[3-[(1S)-1-(dimethylamino)ethyl]phenyl] N-ethyl-N-methylcarbamate
m-((S)-1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate
rivastigmine
40
levodopaPhase 4, Phase 3, Phase 2, Phase 1, Phase 037959-92-76047
Synonyms:
(-)-(3,4-Dihydroxyphenyl)alanine
(-)-3-(3,4-Dihydroxyphenyl)-L-alanine
(-)-3-(3,4-dihydroxyphenyl)-L-alanine
(-)-Dopa
(2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate
(2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid
(−)-3-(3,4-dihydroxyphenyl)-L-alanine
(−)-dopa
.Beta.-(3, 4-Dihydroxyphenyl)alanine
.Beta.-(3,4-Dihydroxyphenyl)-L-alanine
1E83F927-C221-46AA-B90A-81B33C5F3868
2-Amino-3-(3,4-dihydroxyphenyl)propanoic acid
23734-74-9
25525-15-9
3, 4-Dihydroxy-L-phenylalanine
3, 4-Dihydroxyphenylalanine
3,4-DIHYDROXYPHENYLALANINE
3,4-Dihydroxy-L-phenylalanine
3,4-Dihydroxyphenyl-L-alanine
3,4-Dihydroxyphenylalanine
3,4-Dihydroxyphenylalanine (VAN)
3,4-dihydroxy-L-phenylalanine
3,4-dihydroxyphenylalanine
3-(3,4-Dihydroxypheny
3-(3,4-Dihydroxyphenyl)-L-alanine
3-Hydroxy-L-tyrosine
34241-25-3
37830_FLUKA
587-45-1
59-92-7
72572-99-7
72573-00-3
88250-23-1
90638-38-3
AC-11686
AC1L1LOR
AC1Q4U7F
BIDD:GT0158
BPBio1_000059
BSPBio_000053
BSPBio_002354
Bendopa
Bio-0575
Biodopa
Brocadopa
C00355
C9H11NO4
CAS-59-92-7
CCRIS 3766
CHEBI:15765
CHEMBL1009
CID6047
Cerepap
Cidandopa
D 9628
D00059
D0600
D9628
D9628_SIGMA
DAH
DB01235
DOPA
Deadopa
Dihydroxy-L-phenylalanine
Dihydroxyphenylalanine
DivK1c_000452
Dopa
Dopaflex
Dopaidan
Dopal
Dopal-Fher
Dopal-fher
Dopalina
Dopar
Dopar (TN)
Doparkine
Doparl
Dopasol
Dopaston
Dopaston SE
Dopastone
Dopastral
Dopicar
Doprin
EINECS 200-445-2
EU-0100454
Eldopal
Eldopar
Eldopatec
Eurodopa
HMS1568C15
HMS1922J14
HMS2090O08
HMS2093N04
HMS501G14
HSDB 3348
Helfo DOPA
 
Helfo-Dopa
Helfo-dopa
IDI1_000452
IV Levodopa
InChI=1/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14
Insulamina
KBio1_000452
KBio2_000934
KBio2_003502
KBio2_006070
KBioGR_001177
KBioSS_000934
L Dopa
L(-)-Dopa
L-(-)-Dopa
L-(3, 4-Dihydroxyphenyl)-.alpha.-alani
L-(3, 4-Dihydroxyphenyl)alanine
L-(o-Dihydroxyphenyl)alanine
L-.Beta.-(3,4-Dihydroxyphenyl)alanine
L-3,4-Dihydroxyphenylalanine
L-3,4-dihydroxyphenylalanine
L-3-(3,4-Dihydroxyphenyl)-Alanine
L-3-(3,4-Dihydroxyphenyl)alanine
L-3-Hydroxytyrosine
L-4-5-Dihydroxyphenylalanine
L-DOPA
L-DOPA, Parcopa, Atamet, Stalevo, Madopar, Prolopa, Dopar, 3,4-Dihydroxyphenylalanine, Levodopa
L-Dihydroxyphenylalanine
L-Dopa
L-O-Dihydroxyphenylalanine
L-b-(3,4-Dihydroxyphenyl)-a-alanine
L-beta-(3,4-Dihydroxyphenyl)-alpha-alanine
L-beta-(3,4-Dihydroxyphenyl)alanine
L-o-Hydroxytyrosine
LS-255
Laradopa
Larodopa
Ledopa
Levedopa
Levodopa
Levodopa (JP15/USP)
Levodopa (JP15/USP/INN)
Levodopa [USAN:INN:BAN:JAN]
Levodopum
Levodopum [INN-Latin]
Levopa
Lopac-D-9628
Lopac0_000454
MLS000028514
Maipedopa
MolPort-000-856-937
NCGC00015384-01
NCGC00016270-01
NCGC00016270-06
NCGC00093869-04
NINDS_000452
NSC 118381
NSC118381
PDSP1_001541
PDSP2_001525
Parda
Pardopa
Prestwick0_000017
Prestwick1_000017
Prestwick2_000017
Prestwick3_000017
Prestwick_185
Prodopa
Ro 4-6316
S1726_Selleck
SDCCGMLS-0066924.P001
SMR000058312
SPBio_000391
SPBio_001974
SPECTRUM2300205
Sobiodopa
Spectrum2_000496
Spectrum4_000539
Spectrum5_001899
Spectrum_000454
Syndopa
UNII-46627O600J
Veldopa
Weldopa
b-(3,4-Dihydroxyphenyl)-L-alanine
b-(3,4-Dihydroxyphenyl)-a-L-alanine
b-(3,4-Dihydroxyphenyl)alanine
beta-(3,4-Dihydroxyphenyl)-L-alanine
beta-(3,4-Dihydroxyphenyl)-alpha-L-alanine
beta-(3,4-Dihydroxyphenyl)-alpha-alanine
beta-(3,4-Dihydroxyphenyl)alanine
bmse000322
component of Sinemet
l)-L-alanine
nchembio.2007.55-comp26
nchembio.89-comp9
ne
β-(3,4-dihydroxyphenyl)alanine
41
AcetylcholinePhase 4, Phase 3, Phase 2, Phase 175251-84-3187
Synonyms:
ACh
Acetyl choline ion
Acetylcholine Chloride
Acetylcholine cation
 
Acetylcholinium: acetyl-Choline
Choline acetate
Choline acetate (ester)
O-Acetylcholine
acetylcholine chloride
42
AripiprazolePhase 4345129722-12-960795
Synonyms:
129722-12-9
24-29-3
7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydro-2(1H)-quinolinone
7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydrocarbostyril
7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butyloxy)-3,4-dihydro-2(1H)-quinolinone
7-[4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydrocarbostyril
7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one
7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-3,4-dihydroquinolin-2(1H)-one
AC-1554
AC1L1TXZ
AC1Q3T38
ALKS-9070
Abilify
Abilify (TN)
Abilify Discmelt
Abilitat
Aripiprazol
Aripiprazole
Aripiprazole (JAN/USAN/INN)
Aripiprazole [USAN]
Aripiprazolum
Aripirazole
Arpizol
Asprito|
BMS-337039
Bio-0004
Bristol-Myers Squibb brand of aripiprazole
C094645
C12564
C23H27Cl2N3O2
CHEBI:31236
CHEMBL1112
CID60795
CPD000466383
 
D01164
DB01238
Discmelt
FT-0082572
HMS2051I18
HMS2089M20
HMS2093F22
HSDB 7320
KS-1030
L001339
LS-142666
MLS000759517
MLS001165779
MLS001195621
MLS001424078
MolPort-002-885-808
MolPort-003-844-657
NCGC00159510-02
NCGC00159510-03
OPC 31
OPC-14597
OPC-31
Opc 14597
Otsuka brand of aripiprazole
Pripiprazole
S06-0010
SAM001246750
SMR000466383
STK625160
TL8000707
TL80090184
UNII-82VFR53I78
aripiprazol
aripiprazole
aripiprazolum
||OPC 14597
43Dopamine agonistsPhase 4, Phase 3, Phase 2, Phase 1611
44
AmantadinePhase 4, Phase 3, Phase 2, Phase 166768-94-52130
Synonyms:
1-Adamantamine
1-Adamantanamine
1-Adamantanamine (8CI)
1-Adamantylamine
1-Aminoadamantane
1-Aminotricyclo(3.3.1.1(sup 3,7))decane
1-adamantanamine
1-adamantylamine
1-aminoadamantane
138576_ALDRICH
665-66-7 (hydrochloride)
768-94-5
AB00514655
AC-11992
AC1L1CZI
AC1Q4UAF
AC1Q5396
ADAMANTANE,1-AMINO
AKOS000113994
AKOS000119324
Adamantamine
Adamantanamine
Adamantylamine
Amant
Amantadina
Amantadina [INN-Spanish]
Amantadine
Amantadine (INN)
Amantadine Base
Amantadine HCL
Amantadine Hydrochloride
Amantadine [INN:BAN]
Amantadinum
Amantadinum [INN-Latin]
Amantidine
Ambap768-94-5
Aminoadamantane
BIA4304
BIDD:GT0757
BPBio1_000368
BRN 2204333
BSPBio_000334
BSPBio_001570
BSPBio_001822
Bio-0821
C06818
C10H17N
CHEBI:2618
CHEMBL660
CID2130
D07441
DB00915
DivK1c_000815
EINECS 212-201-2
Endantadine
Gen-Amantadine
HMS1791O12
HMS1989O12
HSDB 3202
I14-1101
IDI1_000815
InChI=1/C10H17N/c11-10-4-7-1-8(5-10)3-9(2-7)6-10/h7-9H,1-6,11H
KBio1_000815
KBio2_000390
 
KBio2_002958
KBio2_005526
KBio3_001322
KBioGR_000548
KBioSS_000390
L000868
LS-157049
Lopac-A-1260
Lopac0_000004
Mantadine
MolPort-001-661-700
MolPort-001-760-587
MolPort-001-791-102
NCGC00015036-01
NCGC00015036-07
NCGC00162039-01
NCGC00162039-02
NCGC00162039-03
NCGC00162039-04
NCGC00179597-01
NCIOpen2_001059
NINDS_000815
NSC 341865
NSC341865
NSC83653
OR14310
Oprea1_248648
Pk-Merz
Pk-merz
Prestwick0_000407
Prestwick1_000407
Prestwick2_000407
Prestwick3_000407
SPBio_000002
SPBio_002273
STK298781
Spectrum2_000081
Spectrum3_000291
Spectrum4_000134
Spectrum5_000772
Spectrum_000030
Symadine
Symmetrel
TCMDC-125869
TL8005280
Tricyclo(3.3.1.1(3,7))-decan-1-amine
Tricyclo(3.3.1.1(sup 3,7))decan-1-amine
Tricyclo(3.3.1.1(sup 3.7))decan-1-amine
Tricyclo(3.3.1.13,7)decan-1-amine
Tricyclo[3.3.1.1(3,7)]decan-1-amine
Tricyclo[3.3.1.1(3,7)]decan-1-ylamine
Tricyclo[3.3.1.1(3,7)]decane-1-amine
Tricyclo[3.3.1.1(sup3,7)]decan-1-amine
Tricyclo[3.3.1.1^3,7]decan-1-amine
UNII-BF4C9Z1J53
Viregyt
Virosol
WLN: L66 B6 A B- C 1B ITJ BZ
Wiregyt
adamantan-1-amine
adamantan-1-ylamine
amantadine
amantadine hydrochloride
tricyclo[3.3.1.1(3,7)]decan-1-ylamine
tricyclo[3.3.1.1(3,7)]decane-1-amine
tricyclo[3.3.1.1~3,7~]decan-1-amine
45PiracetamPhase 4, Phase 21687491-74-9
46
BromocriptinePhase 4, Phase 3, Phase 23025614-03-331101
Synonyms:
(5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-3',6',18-trioxoergotaman
(5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)ergotaman-3',6',18-trione
(5'alpha)-2-bromo-12'-hydroxy-5'-(2-methylpropyl)-2'-(propan-2-yl)-3',6',18-trioxoergotaman
(5'alpha)-2-bromo-12'-hydroxy-5'-isobutyl-2'-isopropyl-3',6',18-trioxoergotaman
(6aR,9R)-5-Bromo-N-((2R,5S,10aS,10bS)-10b-hydroxy-5-isobutyl-2-isopropyl-3,6-dioxooctahydro-2H-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide
2-Bromo-12'-hydroxy-2'-(1-methylethyl)-5'-alpha-(2-methylpropyl)ergotamin-3',6',18-trione
2-Bromo-alpha-ergocryptine
2-Bromo-alpha-ergokryptin
2-Bromo-alpha-ergokryptine
2-Bromoergocryptine Methanesulfonate
2-Bromoergokryptine
2-bromo-α-ergocryptine
2-bromo-α-ergokryptin
2-bromo-α-ergokryptine
22260-51-1 (mesylate (salt))
25614-03-3
AC-13601
AC1L1KXS
AC1Q2716
Alti-Bromocriptine
Apo-Bromocriptine
BIDD:GT0464
BPBio1_001131
BRD-K14496212-001-01-1
Bagren
Biomol-NT_000005
Bromergocryptine
Bromocriptin
Bromocriptina
Bromocriptina [INN-Spanish]
Bromocriptine (USAN/INN)
Bromocriptine Methanesulfonate
Bromocriptine [BAN]
Bromocriptine [USAN:BAN:INN]
 
Bromocriptine methanesulfonate
Bromocriptinum
Bromocriptinum [INN-Latin]
Bromocryptin
Bromocryptine
Bromoergocriptine
Bromoergocryptine
C06856
C32H40BrN5O5
CB-154
CCRIS 3244
CHEBI:3181
CHEMBL493
CID31101
D03165
DB01200
EINECS 247-128-5
Ergocryptine, 2-bromo- (8CI)
Ergoset
LS-64540
Lopac0_000171
MolPort-002-512-064
NCGC00024584-04
NCI60_001365
NSC169774
PDSP2_001500
Parlodel
Parlodel Snaptabs
Prestwick0_000121
Prestwick1_000121
Prestwick2_000121
SPBio_002101
UNII-3A64E3G5ZO
bromocriptine
nchembio873-comp18
47
DonepezilPhase 4, Phase 3, Phase 2, Phase 1275120014-06-43152
Synonyms:
( inverted exclamation markA)-E 2020
1-Benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine
120014-06-4
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxy-2,3-dihydroinden-1-one
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one
AB1004836
AC-6969
AC1L1FAE
AKOS000277311
Aricept
Aricept ODT
C24H29NO3
CHEBI:53289
CHEMBL502
CID3152
D07869
DB00843
Domepezil
Donaz
Donaz (TN)
 
Donepezil
Donepezil (INN)
Donepezil [INN:BAN]
Donepezil hydrochloride
Donepezilo
Donepezilum
Eranz
I06-0343
KBio2_002144
KBio2_004712
KBio2_007280
KBioSS_002144
LS-81819
MolPort-000-881-588
MolPort-003-847-014
NCGC00167537-01
Oprea1_188452
Spectrum5_001662
Spectrum_001664
TL8000531
UNII-8SSC91326P
48
LubiprostonePhase 444136790-76-6656719
Synonyms:
(-)-7-((2R,4aR,5R,7aR)-2-(1,1-Difluoropentyl)-2-hydroxy-6-oxooctahydrocyclopenta (b)pyran-5-yl)heptanoic acid
(-)-7-((2R,4aR,5R,7aR)-2-(1,1-Difluoropentyl)-2-hydroxy-6-oxooctahydrocyclopenta(b)pyran-5-yl)heptanoic acid
136790-76-6
333963-40-9
7-((1R,4R,6R,9R)-4-(1,1-difluoropentyl)-4-hydroxy-8-oxo-5-oxabicyclo(4.3.0)non-9-yl)heptanoic acid
7-[(2R,4aR,5R,7aR)-2-(1,1-difluoropentyl)-2-hydroxy-6-oxo-3,4,4a,5,7,7a-hexahydrocyclopenta[b]pyran-5-yl]heptanoic acid
AC-1863
AC1L4IXH
Amitiza
Amitiza, RU-0211, SPI-0211, Lubiprostone
C506401
CHEMBL1201134
CID157920
 
I06-2319
LS-186535
LS-187360
Lubiprostone
Lubiprostone [USAN]
MolPort-006-666-405
RU 0211
RU-0211
RU0211
S1675_Selleck
SPI 0211
SPI-0211
SPI0211
UNII-7662KG2R6K
49
RopinirolePhase 4, Phase 3, Phase 2, Phase 17291374-20-8, 91374-21-95095, 497540
Synonyms:
1,3-Dihydro-4-(2-(dipropylamino)ethyl)-2H-indol-2-one monohydrochloride
2(H)-Indol-2-one, 4-(2-(dipropylamino)ethyl)-1,3-dihydro-, monohydrochloride
2H-Indol-2-one, 1,3-dihydro-4-(2-(dipropylamino)ethyl)-, monohydrochloride
2H-Indol-2-one, 4-[2-(dipropylamino)ethyl]-1,3-dihydro-, hydrochloride (1:1)
4-(2-(Dipropylamino)ethyl)-2-indolinone monohydrochloride
4-[2-(Dipropylamino)ethyl]-1,3-dihydro-2H-indol-2-one
4-[2-(Dipropylamino)ethyl]indoline-2-one
4-[2-(dipropylamino)ethyl]-1,3-dihydro-2H-indol-2-one hydrochloride
4-[2-(dipropylamino)ethyl]-1,3-dihydroindol-2-one
4-[2-(dipropylamino)ethyl]-1,3-dihydroindol-2-one hydrochloride
91374-20-8
91374-20-8 (hydrochloride)
91374-21-9
91374-21-9 (Parent)
AB1004799
AC-735
AC1L1JLL
AC1L2ABS
AC1Q3EQJ
AR-1L3132
Adartrel
BIDD:GT0826
BRD-K15933101-003-01-2
C07564
CHEBI:8888
CHEMBL1200411
CHEMBL589
CID5095
CID68727
D00784
D08489
DB00268
EU-0101101
HMS2093K04
I06-0692
I06-0693
JZP-7
L000520
LS-83828
LS-83890
Lopac-R-4152
Lopac0_001101
 
MolPort-003-666-598
MolPort-003-987-439
NCGC00015893-01
NCGC00015893-04
NCGC00094373-01
NCGC00096064-01
NCGC00096064-02
NVD-434
R 4152
ReQuip
ReQuip CR
ReQuip LP
ReQuip XL
ReQuip XR
Repreve
Requip (TN)
Ropinirol
Ropinirol [INN-Spanish]
Ropinirole
Ropinirole (INN)
Ropinirole HCl
Ropinirole [INN:BAN]
Ropinirole hydrochloride
Ropinirole hydrochloride (JAN/USAN)
Ropinirole hydrochloride [USAN]
Ropinirolum
Ropinirolum [INN-Latin]
Ropitor
Ropitor (TN)
SK&F 101468
SK&F 101468-A
SK&F-101,468
SK&F-101468-A
SK&F-101468A
SKF 101468
SKF 101468-A
SPECTRUM1505178
ST51051236
TL8005858
TL8005859
UNII-030PYR8953
UNII-D7ZD41RZI9
ropinirol
50
NaltrexonePhase 437016590-41-35360515
Synonyms:
16590-41-3
16676-29-2
17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-one
17-(Cyclopropylmethyl)-4,5alpha-epoxy-3,14-dihydroxymorphinan-6-one
3,14-dihydroxy-17-(cyclopropylmethyl)-4,5alpha-epoxymorphinan-6-one
BIDD:GT0405
BPBio1_000146
BRD-K88172511-310-03-8
BRN 3596648
BSPBio_000132
C07253
CCRIS 3506
CHEBI:121459
CHEBI:7465
CHEMBL142
CID5360515
Celupan
D05113
DB00704
Depade
EINECS 240-649-9
EN-1639A
HMS2089O11
HS-0002
HSDB 6750
LS-92094
MLS002153483
MolPort-004-920-221
 
MorViva
N-Cyclopropylmethyl-14-hydroxydihydromorphinone
N-Cyclopropylmethylnoroxymorphone
Naltrexon
Naltrexona
Naltrexona [INN-Spanish]
Naltrexone
Naltrexone (USAN/INN)
Naltrexone Hcl
Naltrexone [USAN:BAN:INN]
Naltrexone [USAN:INN:BAN]
Naltrexone [Usan:Ban:Inn]
Naltrexonum
Naltrexonum [INN-Latin]
PDSP2_000847
PTI-555
Prestwick0_000116
Prestwick1_000116
Prestwick2_000116
Prestwick3_000116
ReVia
SMP1_000206
SPBio_002071
UM-792
UNII-5S6W795CQM
Vivitrex
Vivitrol
Vivitrol (TN)
naltrexone
naltrexone (ReVia)

Interventional clinical trials:

(show top 50)    (show all 1858)
idNameStatusNCT IDPhase
1Trial to Evaluate The Efficacy Of Rotigotine on Parkinson's Disease-Associated Motor Symptoms And ApathyCompletedNCT01782222Phase 4
2Effects of Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's DiseaseCompletedNCT00219284Phase 4
3Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's DiseaseCompletedNCT01049984Phase 4
4Mild Cognitive Impairment in Parkinson's DiseaseCompletedNCT01519271Phase 4
5Rotigotine Versus Placebo to Evaluate the Efficacy on Depressive Symptoms in Idiopathic Parkinson's Disease PatientsCompletedNCT01523301Phase 4
6Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's DiseaseCompletedNCT01723228Phase 4
7Efficacy of Levodopa/Carbidopa/Entacapone vs Levodopa/Carbidopa in Parkinson's Disease Patients With Early Wearing-offCompletedNCT00391898Phase 4
8Study for Rasagiline Effect on Sleep Trial(REST)in Parkinson's DiseaseCompletedNCT01032486Phase 4
9Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated PainCompletedNCT01744496Phase 4
10Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's DiseaseCompletedNCT01018264Phase 4
11The Effects of the Rivastigmine Patch on Parkinson's Disease With Memory and/or Thinking ProblemsCompletedNCT00988117Phase 4
12Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease (PD)CompletedNCT00321854Phase 4
13Dopamine Turnover Rate as Surrogate Parameter for Diagnosis of Early Parkinson's DiseaseCompletedNCT00153972Phase 4
14Placebo-controlled Study in Patients With Parkinson's Disease to Evaluate the Effect of Rotigotine on Non-motor SymptomsCompletedNCT01300819Phase 4
15Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)CompletedNCT01770145Phase 4
16Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine AgonistsCompletedNCT00443872Phase 4
17Duodenal Levodopa Infusion, Quality of Life and Autonomic Nervous System in Parkinson's DiseaseCompletedNCT00914134Phase 4
18Study of Memantine for Gait Disorders And Attention Deficit In Parkinson's DiseaseCompletedNCT01108029Phase 4
19Safety and Efficacy of botulinumA Toxin (BotoxA) for Treatment of Neurogenic Bladder of Parkinson's DiseaseCompletedNCT01421719Phase 4
20Tolerability and Efficacy of Switch From Oral Selegiline to Orally Disintegrating Selegiline (Zelapar) in Patients With Parkinson's DiseaseCompletedNCT00640159Phase 4
21Donepezil to Treat Dementia in Parkinson's DiseaseCompletedNCT00030979Phase 4
22Continuous Delivery of Levodopa in Patients With Advanced Idiopathic Parkinsons Disease - Cost-benefitCompletedNCT00272688Phase 4
23Long-term Study of Duodopa (Levodopa/Carbidopa) in Advanced Parkinson's: Health Outcomes & Net Economic ImpactCompletedNCT00141518Phase 4
24REQUIP (Ropinirole Hydrochloride) IR Long-Term Phase 4 StudyCompletedNCT00485069Phase 4
25A Fixed Dose, Dose Response Study for Ropinirole Prolonged Release in Patients With Early Stage Parkinson's DiseaseCompletedNCT01485172Phase 4
26Naltrexone for Impulse Control Disorders in Parkinson's DiseaseCompletedNCT01052831Phase 4
27Rasagiline for the Symptomatic Treatment of Fatigue in Parkinson's DiseaseCompletedNCT01168596Phase 4
28A Double Blind Placebo Controlled Trial Evaluating Rasagiline Effects on Cognition in Parkinson's Disease Patients With Mild Cognitive Impairment Receiving Dopaminergic TherapyCompletedNCT01497652Phase 4
29Namenda (Memantine) for Non-Motor Symptoms in Parkinson's DiseaseCompletedNCT00646204Phase 4
30Non-motor Symptoms (Depressive Symptoms) of Parkinson's Disease and Their Course Under Pramipexole TreatmentCompletedNCT00651183Phase 4
31Olfaction in Patients With Parkinson's Disease Following Treatment With RasagilineCompletedNCT00902941Phase 4
32Methylphenidate for the Treatment of Gait Impairment in Parkinson's DiseaseCompletedNCT00526630Phase 4
33Study on the Tolerability of Duloxetine in Depressed Patients With Parkinson's DiseaseCompletedNCT00437125Phase 4
34Rasagiline and Apathy in Parkinson's DiseaseCompletedNCT00755027Phase 4
35Effectiveness of Antidepressant Treatment for Depression in People With Parkinson's DiseaseCompletedNCT00304161Phase 4
36Pramipexole Versus Placebo in Parkinson's Disease (PD) Patients With Depressive SymptomsCompletedNCT00297778Phase 4
37Study of Methylphenidate to Treat Gait Disorders And Attention Deficit In Parkinson's Disease (PARKGAIT-II)CompletedNCT00914095Phase 4
38Effect of Undenatured Cysteine-Rich Whey Protein Isolate (HMS 90®) in Patients With Parkinson's DiseaseCompletedNCT01662414Phase 4
39Amitiza in Constipation Associated With PD (Parkinson's Disease)CompletedNCT00908076Phase 4
40Aripiprazole in Patients With Psychosis Associated With Parkinson's DiseaseCompletedNCT00095810Phase 4
41Safety/Efficacy of Tigan® to Control Nausea/Vomiting Experienced During Apokyn® Initiation and TreatmentCompletedNCT00489255Phase 4
42Memantine Versus Placebo in Parkinson's Disease Dementia or Dementia With Lewy BodiesCompletedNCT00855686Phase 4
43A Trial of Neupro® (Rotigotine Transdermal Patch) in Patients With Parkinson's Disease Undergoing SurgeryCompletedNCT00594464Phase 4
44Effect of Intravenous Amantadine on Gait Freezing in Parkinson's DiseaseCompletedNCT01313845Phase 4
45Efficacy and Safety of Levetiracetam Versus Placebo on Levodopa-induced Dyskinesias in Advanced Parkinson's DiseaseCompletedNCT00307450Phase 4
46A Fixed Dose Study of Ropinirole Prolonged Release as Adjunctive Treatment in Patients With Advanced Parkinson's DiseaseCompletedNCT01494532Phase 4
47Ophthalmologic Safety of Long Term Treatment With Pramipexole Compared to Bromocriptine or Other Dopamine Agonists in Patients With Parkinson's DiseaseCompletedNCT02233023Phase 4
48Study to Compare the Effect of Treatment With Carbidopa/Levodopa/Entacapone on the Quality of Life of Patients With Parkinson's Disease. This Study is Not Recruiting in the United StatesCompletedNCT00143026Phase 4
49Virtual Exercises in Patients With Parkinson's Disease.CompletedNCT02023034Phase 4
50The Effect of Rasagiline on Cognition in Parkinson's DiseaseCompletedNCT01382342Phase 4

Search NIH Clinical Center for Parkinson Disease, Late-Onset

Inferred drug relations via UMLS66/NDF-RT44:

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Parkinson Disease, Late-Onset cell therapies at LifeMap Discovery.

Genetic Tests for Parkinson Disease, Late-Onset

About this section

Genetic tests related to Parkinson Disease, Late-Onset:

id Genetic test Affiliating Genes
1 Parkinson Disease25 23 VPS35
2 Parkinson Disease, Late-Onset25

Anatomical Context for Parkinson Disease, Late-Onset

About this section

MalaCards organs/tissues related to Parkinson Disease, Late-Onset:

34
Brain, Subthalamic nucleus, Testes, Bone, Cortex, Eye, Heart

LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Parkinson Disease, Late-Onset:
id TissueAnatomical CompartmentCell Relevance
1 BrainSubstantia Nigra pars CompactaAdult Dopaminergic Neurons Potential therapeutic candidate, affected by disease
2 BrainForebrain White MatterFibrous Astrocyte Cells Potential therapeutic candidate
3 AdiposeSubcutaneous White AdiposeMesenchymal Stem Cells Potential therapeutic candidate
4 BrainNeocortexProtoplasmic Astrocyte Cells Potential therapeutic candidate
5 AdiposeSubcutaneous White AdiposeStromal Cells Potential therapeutic candidate

Animal Models for Parkinson Disease, Late-Onset or affiliated genes

About this section

MGI Mouse Phenotypes related to Parkinson Disease, Late-Onset:

39
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:000539411.0MAPT, PINK1, SLC6A3, SNCA
2MP:000538410.9GBA, GDNF, LRRK2, MAOB, MAPT, PARK2
3MP:000301210.9LRRK2, MAPT, PARK2, PINK1, SNCA, TBP
4MP:001076810.7ADH1C, ATXN2, GBA, GDNF, LRRK2, MAPT
5MP:000363110.6ATXN2, ATXN3, GBA, GDNF, LRRK2, MAOB
6MP:000537610.6ADH1C, ATXN2, ATXN3, GBA, LRRK2, MAOB
7MP:000538510.5GBA, GDNF, LRRK2, MAPT, PARK2, PINK1
8MP:000537810.4ADH1C, ATXN2, GBA, GDNF, MAPT, PARK2
9MP:000538610.3ATXN2, ATXN3, GBA, GDNF, LRRK2, MAOB

Publications for Parkinson Disease, Late-Onset

About this section

Variations for Parkinson Disease, Late-Onset

About this section

UniProtKB/Swiss-Prot genetic disease variations for Parkinson Disease, Late-Onset:

68
id Symbol AA change Variation ID SNP ID
1PARK2p.Cys253TyrVAR_019749rs747427602
2PARK2p.Arg256CysVAR_019750rs150562946
3PARK2p.Arg275TrpVAR_019752rs34424986
4PARK2p.Asp280AsnVAR_019753rs72480422

Clinvar genetic disease variations for Parkinson Disease, Late-Onset:

5 (show all 21)
id Gene Variation Type Significance SNP ID Assembly Location
1VPS13CNM_020821.2(VPS13C): c.8445+2T> Gsingle nucleotide variantPathogenicrs869312809GRCh37Chr 15, 62207830: 62207830
2VPS13CNM_020821.2(VPS13C): c.806_807insCAGA (p.Arg269Serfs)insertionPathogenicGRCh37Chr 15, 62305256: 62305257
3VPS13CNM_020821.2(VPS13C): c.9568G> T (p.Glu3190Ter)single nucleotide variantPathogenicrs869312810GRCh37Chr 15, 62174851: 62174851
4VPS13CNM_020821.2(VPS13C): c.4165G> C (p.Gly1389Arg)single nucleotide variantPathogenicrs369100678GRCh37Chr 15, 62250807: 62250807
5VPS13CNM_020821.2(VPS13C): c.4777delC (p.Gln1593Lysfs)deletionPathogenicrs869312811GRCh37Chr 15, 62239491: 62239491
6LRRK2NM_198578.3(LRRK2): c.4321C> A (p.Arg1441Ser)single nucleotide variantPathogenicrs33939927GRCh37Chr 12, 40704236: 40704236
7GBANM_000157.3(GBA): c.1448T> C (p.Leu483Pro)single nucleotide variantPathogenic, risk factorrs421016GRCh37Chr 1, 155205043: 155205043
8GBANM_000157.3(GBA): c.1448T> C (p.Leu483Pro)single nucleotide variantPathogenic, risk factorrs421016GRCh37Chr 1, 155205043: 155205043
9GLUD2NM_012084.3(GLUD2): c.1492T> G (p.Ser498Ala)single nucleotide variantPathogenicrs9697983GRCh37Chr X, 120183030: 120183030
10ATXN3NM_004993.5(ATXN3): c.892_894CAG(8_36) (p.Gln298_Gln305=)NT expansionPathogenic, risk factorrs193922928GRCh37Chr 14, 92537355: 92537357
11GBANM_000157.3(GBA): c.1448T> C (p.Leu483Pro)single nucleotide variantPathogenic, risk factorrs421016GRCh37Chr 1, 155205043: 155205043
12GBANM_001005741.2(GBA): c.1226A> G (p.Asn409Ser)single nucleotide variantPathogenic, risk factorrs76763715GRCh37Chr 1, 155205634: 155205634
13GBANM_000157.3(GBA): c.1504C> T (p.Arg502Cys)single nucleotide variantPathogenic, risk factorrs80356771GRCh37Chr 1, 155204987: 155204987
14GBANM_000157.3(GBA): c.1448T> C (p.Leu483Pro)single nucleotide variantPathogenic, risk factorrs421016GRCh37Chr 1, 155205043: 155205043
15GBANM_001005741.2(GBA): c.1444G> A (p.Asp482Asn)single nucleotide variantrisk factorrs75671029GRCh37Chr 1, 155205047: 155205047
16DNAJC13NM_015268.3(DNAJC13): c.2564A> G (p.Asn855Ser)single nucleotide variantPathogenicrs387907571GRCh37Chr 3, 132196839: 132196839
17ATXN8OSNR_002717.2(ATXN8OS): n.1103_1105CTG(15_40)NT expansionPathogenic, risk factorrs193922930GRCh37Chr 13, 70713516: 70713518
18ATXN2NM_002973.3(ATXN2): c.496_498CAG(15_24) (p.Gln188_Pro189insGlnGln)NT expansionrisk factorrs193922927GRCh37Chr 12, 112036785: 112036787
19TBPNM_003194.4(TBP): c.172_174CAG(25_42) (p.Gln95(25_42))NT expansionPathogenic, risk factorrs193922935GRCh37Chr 6, 170870996: 170870998
20MT-ND1m.3397A> Gsingle nucleotide variantPathogenicrs199476120GRCh37Chr MT, 3397: 3397
21MAPTNM_016835.4(MAPT): c.1838_1840delATA (p.Asn613del)deletionPathogenic, risk factorrs63751392GRCh37Chr 17, 44087740: 44087742

Copy number variations for Parkinson Disease, Late-Onset from CNVD:

6 (show all 18)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1236911173049146173078950Copy numberPAPPA2Parkinson disease
22743312083253420850591Genomic rearrangemen tsPINK1Parkinson disease
360306118494899384958207Copy numberDLG2Parkinson disease
4115237175558158255809920Copy numberUSP32Parkinson disease
5132540195931064859326954Genomic rearrangemen tsPRPF31Parkinson disease
61708953161200000193800000Copy numberEIF4G1Parkinson disease
718657043690000088200000Duplication or tripl icationSNCAParkinson disease
818737544830000099100000Copy numberSNCAParkinson disease
918921947152887371716513Copy numberENAMParkinson disease
1019041948820000094000000TriplicationSNCAParkinson disease
1119079349064525090759447DuplicationSNCAParkinson disease
1219080749086572790978470Duplication or tripl icationSNCAParkinson disease
131954895151389412151513092Copy numberGLRA1Parkinson disease
142077846161000000164500000Gain or lossPARK2Parkinson disease
152078566161768590163148834Copy numberPARK2Parkinson disease
162079376162471089162677104Copy numberPARK2Parkinson disease
172117386336751356443DeletionIRF4Parkinson disease
1823766482503847225171648Copy numberParkinson disease

Expression for genes affiliated with Parkinson Disease, Late-Onset

About this section
Search GEO for disease gene expression data for Parkinson Disease, Late-Onset.

Pathways for genes affiliated with Parkinson Disease, Late-Onset

About this section

GO Terms for genes affiliated with Parkinson Disease, Late-Onset

About this section

Cellular components related to Parkinson Disease, Late-Onset according to GeneCards Suite gene sharing:

(show all 14)
idNameGO IDScoreTop Affiliating Genes
1mitochondrial respiratory chain complex IGO:000574711.3MT-ND1, PARK7, SNCA
2Lewy bodyGO:009741311.3PARK2, PINK1
3inclusion bodyGO:001623411.2LRRK2, SNCA
4mitochondrial membraneGO:003196611.2ATXN3, LRRK2, MT-ND1
5mitochondrial outer membraneGO:000574111.0LRRK2, MAOB, PINK1, VPS13C
6synaptic vesicleGO:000802110.9LRRK2, SNCA, TH
7cell bodyGO:004429710.8MAPT, PARK7, PINK1
8neuron projectionGO:004300510.8LRRK2, PARK2, PARK7, SLC6A3, TH
9presynapseGO:009879310.8PARK2, PARK7, SLC6A3
10cytosolGO:000582910.7ADH1C, ATXN3, LRRK2, MAPT, PARK2, PARK7
11axonGO:003042410.7LRRK2, MAPT, PARK7, PINK1, SLC6A3, SNCA
12mitochondrionGO:000573910.5LRRK2, MAOB, MT-ND1, PARK2, PARK7, PINK1
13terminal boutonGO:004319510.5LRRK2, SNCA, TH
14cytoplasmGO:000573710.3ATXN2, ATXN3, DNAJC13, LRRK2, MAPT, PARK2

Biological processes related to Parkinson Disease, Late-Onset according to GeneCards Suite gene sharing:

(show all 44)
idNameGO IDScoreTop Affiliating Genes
1regulation of synaptic vesicle transportGO:190280311.1LRRK2, PARK2, PINK1
2negative regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathwayGO:190337711.1PARK2, PARK7
3negative regulation of oxidative stress-induced cell deathGO:190320211.1PARK2, PARK7, PINK1
4cellular response to toxic substanceGO:009723711.1PARK2, PINK1
5positive regulation of mitochondrial electron transport, NADH to ubiquinoneGO:190295811.1PARK7, PINK1
6negative regulation of hydrogen peroxide-induced neuron intrinsic apoptotic signaling pathwayGO:190338411.1PARK7, PINK1
7dopamine uptake involved in synaptic transmissionGO:005158311.1PARK2, PARK7, SLC6A3, SNCA
8negative regulation of hydrogen peroxide-induced cell deathGO:190320611.1LRRK2, PARK7
9negative regulation of late endosome to lysosome transportGO:190282311.1LRRK2, VPS35
10cellular response to manganese ionGO:007128711.1LRRK2, PARK2, TH
11negative regulation of oxidative stress-induced neuron deathGO:190320411.1PARK7, PINK1
12regulation of protein targeting to mitochondrionGO:190321411.1PARK2, PINK1
13exploration behaviorGO:003564011.0ATXN3, LRRK2
14negative regulation of autophagosome assemblyGO:190290211.0LRRK2, PINK1
15negative regulation of macroautophagyGO:001624211.0LRRK2, PINK1
16regulation of mitochondrial membrane potentialGO:005188111.0PARK2, PARK7, PINK1
17negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathwayGO:190223611.0LRRK2, PARK2, PARK7
18regulation of protein ubiquitinationGO:003139611.0PARK2, PINK1
19positive regulation of dopamine secretionGO:003360311.0GDNF, PINK1
20negative regulation of neuron deathGO:190121511.0LRRK2, PARK2, PARK7, SNCA
21neurotransmitter biosynthetic processGO:004213611.0SLC6A3, TH
22dopamine catabolic processGO:004242010.9MAOB, SLC6A3
23regulation of reactive oxygen species metabolic processGO:200037710.9PARK2, PINK1, SNCA
24regulation of neuron deathGO:190121410.9LRRK2, SNCA
25cellular response to oxidative stressGO:003459910.9LRRK2, PARK7, PINK1, SNCA
26dopamine biosynthetic processGO:004241610.9SLC6A3, SNCA, TH
27mitochondrion organizationGO:000700510.9LRRK2, PARK2, PARK7, PINK1, VPS13C
28cellular response to dopamineGO:190335110.9LRRK2, PARK2
29protein localization to mitochondrionGO:007058510.9LRRK2, PARK2
30positive regulation of peptidyl-serine phosphorylationGO:003313810.9PARK7, PINK1, SNCA
31regulation of mitochondrion organizationGO:001082110.9PARK2, PINK1
32positive regulation of mitochondrial fissionGO:009014110.9PARK2, PINK1
33negative regulation of protein phosphorylationGO:000193310.9LRRK2, PARK2, PARK7, SNCA
34negative regulation of neuron apoptotic processGO:004352410.9GDNF, PARK2, PARK7, PINK1, SNCA
35regulation of autophagyGO:001050610.8LRRK2, MAPT, PARK2
36regulation of dopamine secretionGO:001405910.7PARK2, SNCA
37response to drugGO:004249310.7MAOB, MT-ND1, PARK7, SLC6A3, SNCA, TH
38locomotory behaviorGO:000762610.7PARK2, SLC6A3, TH
39regulation of locomotionGO:004001210.6LRRK2, SNCA
40regulation of dopamine metabolic processGO:004205310.5PARK2, SLC6A3
41synaptic transmission, dopaminergicGO:000196310.5PARK2, PARK7, SNCA, TH
42regulation of neurotransmitter secretionGO:004692810.5PARK2, SNCA
43adult locomotory behaviorGO:000834410.4GDNF, PARK2, PARK7, SNCA
44dopamine metabolic processGO:004241710.2PARK2, SNCA

Molecular functions related to Parkinson Disease, Late-Onset according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1ubiquitin-specific protease bindingGO:199038110.8PARK2, PARK7
2phospholipase bindingGO:004327410.7PARK2, SNCA
3enzyme bindingGO:001989910.6MAPT, PARK2, PARK7, SNCA, TBP, TH
4dopamine bindingGO:003524010.5SLC6A3, TH

Sources for Parkinson Disease, Late-Onset

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
25GTR
26HGMD
27HMDB
28ICD10
29ICD10 via Orphanet
30ICD9CM
31IUPHAR
32KEGG
35MedGen
37MeSH
38MESH via Orphanet
39MGI
42NCI
43NCIt
44NDF-RT
47NINDS
48Novoseek
50OMIM
51OMIM via Orphanet
55PubMed
56QIAGEN
61SNOMED-CT via Orphanet
65Tumor Gene Family of Databases
66UMLS
67UMLS via Orphanet